



**Point-of-Care Assessment of Platelet Reactivity in the  
Emergency Department May Facilitate Rapid Rule-Out of  
Acute Coronary Syndromes: A Prospective Cohort Pilot  
Feasibility Study**



Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003883
Article Type:	Research
Date Submitted by the Author:	23-Aug-2013
Complete List of Authors:	Darling, Chad; University of Massachusetts Medical School, Emergency Medicine Sala Mercado, Javier; Instituto Modelo de Cardiologia Privado SRL, Quiroga-Castro, Walter; Instituto Modelo de Cardiologia Privado SRL, Tecco, Gabriel; Instituto Modelo de Cardiologia Privado SRL, Zelaya, Felix; Instituto Modelo de Cardiologia Privado SRL, Conci, Eduardo; Instituto Modelo de Cardiologia Privado SRL, Sala, Jose; Instituto Modelo de Cardiologia Privado SRL, Smith, Craig; University of Massachusetts Medical School, Cardiovascular Medicine Michelson, Alan; Harvard Medical School, Whittaker, Peter; Wayne State University School of Medicine, Cardiovascular Research Institute Welch, Rob; Wayne State University, ; Wayne State University School of Medicine, Cardiovascular Research Institute Przyklenk, Karin; Wayne State University School of Medicine, Cardiovascular Research Institute
<b>Primary Subject Heading</b>:	Emergency medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Myocardial infarction < CARDIOLOGY, Adult cardiology < CARDIOLOGY

SCHOLARONE™  
Manuscripts

Word count (excluding title page, abstract, references, figure legends and tables): 3,406

**Point-of-Care Assessment of Platelet Reactivity  
in the Emergency Department  
May Facilitate Rapid Rule-Out of Acute Coronary Syndromes:  
A Prospective Cohort Pilot Feasibility Study**

Chad E. Darling MD\*, Javier A. Sala Mercado MD PhD<sup>§†\*\*</sup>,  
Walter Quiroga-Castro MD\*\*, Gabriel F. Tecco MD\*\*, Felix R. Zelaya MD\*\*,  
Eduardo C. Conci MD\*\*, Jose P. Sala MD\*\*, Craig S. Smith MD<sup>£</sup>,  
Alan D. Michelson MD<sup>†</sup>, Peter Whittaker PhD<sup>\*§†¶</sup>, Robert D. Welch MD<sup>§¶</sup>  
and Karin Przyklenk PhD<sup>\*§†¶</sup>

Departments of \*Emergency Medicine and <sup>£</sup> Cardiovascular Medicine,  
University of Massachusetts Medical School,  
Worcester, MA USA

\*\* Division of Cardiology, Instituto Modelo de Cardiologia Privado SRL,  
Cordoba, Argentina

<sup>†</sup> Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital,  
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

<sup>§</sup> Cardiovascular Research Institute and  
Departments of <sup>¶</sup> Emergency Medicine and <sup>‡</sup> Physiology,  
Wayne State University School of Medicine Detroit, MI USA

Short title: Platelet activation and rule-out of ACS

Key words: acute coronary syndromes, platelet, emergency department:

Correspondence: Karin Przyklenk, PhD  
Cardiovascular Research Institute,  
Wayne State University School of Medicine,  
Elliman Building, Room 1107,  
421 E. Canfield,  
Detroit, MI 48201 USA

Telephone: 313-577-9047  
E-mail: [kprzykle@med.wayne.edu](mailto:kprzykle@med.wayne.edu)

**ABSTRACT**

**Objective:** Accurate, efficient and cost-effective disposition of patients presenting to emergency departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS) is a growing priority. Platelet activation is an early feature in the pathogenesis of ACS; thus, we sought to obtain preliminary insight into whether point-of-care testing of platelet function: (i) is feasible in the ED; and (ii) may provide additional predictive value to assist in the rule-out of ACS.

**Design:** Prospective cohort feasibility study.

**Setting:** Two urban tertiary care sites, one located in the United States and the second in Argentina.

**Participants:** 509 adult patients presenting with symptoms of ACS as determined by the treating physician(s).

**Intervention:** none.

**Main outcome measures:** Platelet reactivity was quantified using the Platelet Function Analyzer (PFA)-100<sup>®</sup>, with closure time (i.e., time [seconds] required for blood, aspirated under high shear, to occlude a 150  $\mu\text{m}$  aperture) serving as the primary endpoint. Closure times were categorized as 'normal' or 'prolonged', defined objectively as the 90<sup>th</sup> percentile of the distribution for all subjects enrolled in the study. Diagnosis of ACS was made using standard criteria.

**Results:** Closure times for the study population ranged from 47-300 seconds, with a 90<sup>th</sup> percentile value of 138 seconds. The proportion of patients with closure times  $\geq 138$  seconds was significantly higher in the ACS-negative group (41/330; 12.4%) *versus* the ACS-positive cohort (2/105 [1.9%];  $p=0.0006$ ). The specificity of 'prolonged' closure times ( $\geq 138$  seconds) for a diagnosis of ACS-negative was 98.1%, with a positive predictive power of 95.4%.

Multivariate analysis revealed that closure time provided incremental, independent predictive value in the rule-out of ACS.

1  
2  
3 **Conclusion:** Point-of-care assessment of platelet reactivity is feasible in the Emergency  
4  
5 Department and may facilitate the rapid rule-out of ACS in patients with prolonged closure  
6  
7 times. Further large-scale multi-center investigation, incorporating risk/benefit analysis, is  
8  
9 warranted.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ARTICLE SUMMARY

### Article focus:

- The development of accurate, efficient and cost-effective strategies to assist in the rapid rule-out of acute coronary syndromes (ACS) in the Emergency Department is a growing priority.
- Platelet activation is an early feature in the pathogenesis of ACS.
- Our aims in this pilot feasibility study were to investigate whether point-of-care testing of platelet function, assessed by measuring 'closure time' using the Platelet Function Analyzer (PFA)-100<sup>®</sup>: (i) is logistically feasible in the ED; and (ii) provides additional predictive value, beyond that obtained via routine clinical assessment, to assist in the rule-out of ACS.

### Key messages:

- Point-of-care testing of platelet reactivity is feasible in the ED.
- ACS-negative *versus* ACS-positive patients were distinguished by differences in the proportion of patients with prolonged closure times.
- Measurement of closure time provided incremental, independent predictive value in the rule-out of ACS.

### Strengths and Limitations:

- The study suggests that a technically straightforward and cost-effective test, with minimal patient risk, may serve as a useful adjunct to current, standard ED practices for the rule-out of ACS. Importantly, the results are generalizable: the observation of a higher incidence of prolonged closure times in ACS-negative patients was seen in subjects from two distinct health care systems and populations.
- PFA testing will only contribute to the identification of a subset of ACS-negative patients, with both the size of the subset and potential value of the test dependent on the threshold used to define 'prolonged' closure times.

- Limitations of this pilot study include the enrollment of patients via convenience sampling, the fact that patient outcomes were not monitored beyond hospital discharge, and that a risk/benefit analysis was not included in the study design.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Accurate, efficient and cost-effective diagnosis of patients presenting to emergency  
4 departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS) – and, in  
5 particular, the exclusion and early discharge of patients with non-cardiac chest pain – is a  
6 growing priority [1, 2]. In an effort to meet this challenge, interest has focused on the  
7 identification of new approaches to augment standard ED procedures and facilitate the timely  
8 triage of patients with suspected ACS. For example, there is recent evidence that coronary CT  
9 angiography (CCTA) combined with routine clinical assessment may provide added prognostic  
10 value in the management of chest pain patients in the ED [3-8]. Use of CCTA in low-to-  
11 intermediate risk patients is reportedly safe and reduces ED costs and hospital length of stay [3-  
12 5, 7, 8]. However, these benefits are accompanied by exposure to radiation and associated  
13 with increases in diagnostic testing and subsequent invasive procedures [5, 8].

14  
15  
16 Assessment of platelet activation, an early feature in the pathogenesis of ACS [9-14],  
17 has also been investigated as a possible benign strategy to expedite the diagnosis of ACS [15,  
18 16]. Application of flow cytometry, the 'gold standard' for the quantitation of molecular indices of  
19 platelet activation, is, however, impractical for routine use under emergent conditions [11, 12,  
20 17, 18]. More importantly, classic molecular indices of platelet activation have not provided  
21 added benefit in the risk stratification of undifferentiated chest pain patients [15, 16].

22  
23 We hypothesized that rapid assessment of platelet reactivity using a technically  
24 straightforward point-of-care device – specifically, the Platelet Function Analyzer (PFA)-100<sup>®</sup>  
25 (Siemens) – may represent a more feasible strategy to assist in the timely rule- out of ACS in  
26 the ED. Rather than quantifying molecular markers of platelet activation-aggregation, the output  
27 of the PFA-100<sup>®</sup> is 'closure time': that is, the time required for whole blood, aspirated under high  
28 shear, to occlude a small, 150 µm aperture in a membrane coated with standard platelet  
29 agonists (collagen-adenosine diphosphate [ADP] or collagen-epinephrine). Although the PFA-  
30 100<sup>®</sup> is typically utilized to investigate the responsiveness of patients to aspirin and other anti-  
31 platelet therapies and aid in the detection of platelet dysfunction [11, 12, 18-22], there is

1  
2  
3 evidence to suggest that shortened closure times may be a marker of the acuity of coronary  
4 disease [10]. Accordingly, our primary aims in this pilot study were to determine whether: (i)  
5 point-of-care testing of platelet function is logistically feasible in an emergent setting; (ii)  
6 assessment of closure times provides a specific test, with robust positive predictive value, for  
7 the rule-out of ACS, and (iii) closure time yields additional predictive value, beyond that obtained  
8 via routine clinical assessment, that may assist in the identification of ACS-negative *versus*  
9 ACS-positive patients. In addition, as a secondary analysis, we investigated whether closure  
10 time may be of value in discriminating among ST-elevation myocardial infarction (STEMI), non-  
11 ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **METHODS**

27  
28 We conducted a prospective cohort feasibility study of patients presenting with potential  
29 ACS at two urban tertiary care sites: the Emergency Department at the University of  
30 Massachusetts (UMASS)-Memorial Medical Center, University Campus, Worcester, MA USA,  
31 and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL, Cordoba,  
32 Argentina. The enrollment period was from January 2007 to December 2010, with patients  
33 entered on a convenience basis (i.e., enrollments were not consecutive but, rather, coincided  
34 with the work schedules of the study investigators). The protocol was reviewed and approved by  
35 the respective Institutional Review Boards at both institutions.  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 ***Patient Population***

46  
47 Patients  $\geq 18$  years of age with a potential diagnosis of ACS (at the discretion of the  
48 treating physician and reflected by orders for an electrocardiogram (ECG) and cardiac  
49 biomarkers) were considered for enrollment in the study. Prospective exclusion criteria were  
50 pregnancy, renal insufficiency (defined as serum creatine levels  $\geq 1.5$  mg/dl), anemia  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 (hematocrit <30%), platelet count <100,000/ $\mu$ L, major bleeding, any gastrointestinal bleeding,  
4  
5  
6 trauma, or inability to provide informed consent for any reason.

### 7 **Study Enrollment and Protocol**

8  
9  
10 As soon as possible after evaluation by ED staff, potential subjects were approached for  
11  
12 enrollment into the study. If the patient was too ill or otherwise unable to provide written  
13  
14 consent, then proxy consent was attempted. If consent was obtained by proxy and the patient  
15  
16 later became cognizant, they were given the option to continue or withdraw their participation in  
17  
18 the study. If consent was withdrawn, all collected data were discarded.  
19

20  
21 Blood used in the PFA-100<sup>®</sup> was drawn early in the ED stay, at the same time as cardiac  
22  
23 biomarker testing, and closure time was measured within 3 hours of collection. All samples  
24  
25 were obtained via peripheral venipuncture and drawn into tubes containing 3.2% sodium citrate.  
26  
27 Immediately before analysis, each sample was gently inverted; a 900  $\mu$ L aliquot of whole blood  
28  
29 was then applied to a collagen-ADP test cartridge and closure time was quantified. Maximum  
30  
31 test duration for the PFA-100<sup>®</sup> is 5 minutes; if the aperture is not occluded within this period, a  
32  
33 closure time of '>300 seconds' is displayed.  
34

35  
36 Upon enrollment, patients were questioned regarding a history of bleeding or platelet  
37  
38 function disorders and ingestion of known anti-platelet agents within the past 7 days (aspirin,  
39  
40 clopidogrel, non-steroidal anti-inflammatory agents). In addition, the medical record was  
41  
42 reviewed and standard cardiac risk factors (diabetes, hypertension, hypercholesterolemia,  
43  
44 smoking, family history of heart disease) were recorded and used in the calculation of TIMI risk  
45  
46 score [23].  
47

### 48 **Patient Diagnosis**

49  
50 Final diagnosis (ACS-negative *versus* ACS-positive) was established via standardized  
51  
52 chart review. All reviews were conducted by physicians in a blinded manner, without knowledge  
53  
54 of the closure time data. For subjects enrolled at the Instituto Modelo de Cardiologia Privado,  
55  
56 all reviews were performed by cardiologists. At UMASS, each chart was initially reviewed by an  
57  
58  
59  
60

1  
2  
3 ED physician (CED). For patients with a definitive diagnosis of ACS-negative, no additional  
4 review was performed. However, for patients who: (i) had positive cardiac biomarkers during  
5 admission; (ii) underwent cardiac catheterization; (iii) had a positive provocative cardiovascular  
6 test (e.g., exercise stress test); and/or (iv) had ischemic ECG changes, the chart was reviewed  
7 by a cardiologist. In addition, in any case in which the diagnosis was uncertain, the decision was  
8 adjudicated by a cardiologist (CSS).  
9

10  
11  
12 Patients considered to be ACS-positive were categorized into one of three groups: (i)  
13 STEMI, defined as 1 mm ST segment elevation in at least 2 contiguous ECG leads, a history  
14 consistent with ACS, and/or cardiac catheterization findings consistent with acute coronary  
15 occlusion; (ii) NSTEMI, defined as any ECG finding other than STEMI, history and inpatient  
16 cardiac testing consistent with ACS, and positive diagnostic cardiac markers within 24 hours of  
17 hospital arrival; or (iii) UA, defined as any ECG findings, a history consistent with ACS, non-  
18 diagnostic cardiac markers within 24 hours of arrival, and/or cardiac diagnostic testing (e.g.,  
19 cardiac catheterization) consistent with ACS. Patients who did not meet these criteria (those  
20 with a diagnosis of non-cardiac chest pain/symptoms) were classified as ACS-negative.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 **Statistical Analysis**

37  
38 Our target sample size in this exploratory study was empiric. We reasoned that, as an  
39 approximate order of magnitude, ~100 patients would be required in the ACS-positive group in  
40 order to have a likelihood of discerning a potential difference in closure times between ACS-  
41 negative and ACS-positive groups. Assuming that 75% of patients enrolled in the study would  
42 be ACS-negative (and thus 25% would be ACS-positive), a total of approximately 400 patients  
43 would be required. To account for exclusions, target enrollment was set at ~500 subjects.  
44  
45  
46  
47  
48  
49  
50

### 51 Univariate comparisons

52  
53 Our primary analyses focused on the comparison of patients in the two main outcome  
54 groups: ACS-negative *versus* ACS-positive. All categorical data were compared using the  
55 Fisher's Exact Test and are reported as percentages. For continuous data, the D'Agostino and  
56  
57  
58  
59  
60

1  
2  
3 Pearson Test was applied to determine normality and the appropriate parametric (t-test) or non-  
4  
5 parametric alternative (Mann-Whitney) tests were utilized. Secondary analysis (comparison of  
6  
7 closure times among ACS-negative, STEMI, NSTEMI and UA groups) was conducted using the  
8  
9 Kruskal-Wallis test. Results are reported as mean  $\pm$  standard deviation or medians with  
10  
11 associated 10<sup>th</sup> and 90<sup>th</sup> percentile ranges.

#### 14 Sensitivity, specificity and multivariate analysis

16 Closure time was categorized into “normal” and “prolonged” values based on the 90<sup>th</sup>  
17  
18 percentile of the distribution for all patients enrolled in the study. Utilizing the normal and  
19  
20 prolonged values of closure time, the sensitivity, specificity, negative and positive predictive  
21  
22 values for identifying **ACS-negative** patients were determined. Two reasons contributed to our  
23  
24 choice of ACS negative (rather than ACS positive) as the main outcome of interest: (i) this  
25  
26 approach is consistent with current guidelines for the improvement of diagnostic accuracy [1, 8];  
27  
28 and (ii) we reasoned that prolonged closure times may be associated with the absence of ACS,  
29  
30 whereas shorter closure times may be manifest in either ACS negative or ACS positive patients.  
31  
32 Sensitivity, specificity and predictive values are reported with associated 95% confidence  
33  
34 intervals.  
35  
36

37  
38 To determine if PFA closure time provides additional predictive value to standard clinical  
39  
40 diagnostic information, a logistic regression was developed to assess its independent  
41  
42 association with the main outcome of ACS-negative. Independent predictor variables  
43  
44 considered to be mandatory in the model were platelet closure time (utilizing continuous rather  
45  
46 than the categorized values; the main predictor of interest) and the TIMI risk score (representing  
47  
48 standard clinical information to predict ACS outcomes). To account for potential differences  
49  
50 between UMASS and Cordoba, study site was also added to the regression model. Other non-  
51  
52 mandatory variables considered for inclusion were sex, a medical history of diabetes,  
53  
54 hypertension, hypercholesterolemia, smoking, and clopidogrel use. As age and aspirin use are  
55  
56 individually incorporated in the TIMI risk score, these variables were not considered for separate  
57  
58  
59  
60

1  
2  
3 inclusion in the model. Non-mandatory variables were left in the model only if they yielded an  
4 increase in predictive value as determined by ROC (receiver operating characteristic) analysis  
5 or were of additional importance based on the 2 log likelihood ratio test.  
6  
7  
8

9  
10 The reported estimate and adjusted odds ratio for closure time were calculated for an  
11 increase in platelet closure time of 10 seconds (rather than 1 second), a choice based on the  
12 premise that a 1-second increase would be of limited clinical usefulness. The final model was  
13 evaluated by c-statistic (area under the ROC curve) and the Hosmer and Lemeshow fit test. As  
14 a sensitivity test, the results were calculated using the general estimating equation (PROC  
15 GENMOD) with study site evaluated as a subject factor (cluster) rather than a term in the model.  
16  
17  
18  
19  
20  
21

22 Analyses were performed using GraphPad Prism Version 5.04 (San Diego CA) and  
23 SAS Version 9.3, (Carey NC).  
24  
25  
26  
27  
28

## 29 RESULTS

### 30 *Enrollment and exclusions* (Figure 1)

31  
32 A combined total of 509 patients were enrolled at the two study sites. Sixty-one subjects  
33 were excluded because closure time data were not available: reasons included technical errors  
34 (n=14), closure times >300 seconds (possibly due to mild thrombocytopenia, anemia, or  
35 inadequate mixing of the blood sample prior to testing; n=36), and failure to measure closure  
36 time despite obtaining consent (n=11). An additional 5 subjects were removed from analysis  
37 because exclusion criteria were identified after consent was obtained (n=4), or consent was  
38 revoked after the blood sample was collected (n=1). For the remaining 443 patients in whom  
39 closure time was quantified, 8 were diagnosed with thrombotic events that were non-cardiac in  
40 origin and thus were excluded from further analysis. Accordingly, results are reported for 435  
41 subjects (324 enrolled at UMASS and 111 enrolled in Cordoba): 105 were diagnosed with ACS  
42 and 330 were ACS-negative patients.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Demographics** (Table 1)

As expected [24], the ACS-positive group had higher TIMI scores, was older, and had a higher proportion of male patients when compared with the ACS-negative cohort. In addition, the incidence of hypercholesterolemia and use of clopidogrel were significantly higher in the ACS group. There were, however, no differences in the use of aspirin, incidence of hypertension or diabetes, proportion of smokers or reported family history of heart disease between the two groups.

### **Closure time** (Figure 2 and Table 2)

There was a modest but significant difference in median closure times in the ACS-negative *versus* ACS-positive groups: 91 *versus* 87 seconds, respectively ( $p=0.0061$ ; Figure 2A).

Of potentially greater importance, the two groups were distinguished by differences in the proportion of patients with prolonged closure times. We found that 41/330 (12.4%) of ACS-negative subjects had closure times  $\geq 138$  seconds (i.e., the 90<sup>th</sup> percentile of the distribution for all patients enrolled in the study) while, in contrast, 2/105 (1.9%) of patients in the ACS-positive group had closure times  $\geq$  this value ( $p=0.0006$ ; Figure 2B and Table 2A). The specificity and sensitivity of 'prolonged' closure times ( $\geq 138$  seconds) for a diagnosis of ACS-negative were 98.1% and 12.4%, respectively, with positive a positive predictive value of 95.4% and negative predictive value of 26.3% (Table 2B).

When the ACS-positive group was divided into STEMI, NSTEMI and UA cohorts, differences in closure time in the secondary 4-group analysis remained significant ( $p=0.0005$ ; Figure 2C). However, post-hoc pairwise comparisons revealed no significant differences among STEMI, NSTEMI and UA groups.

### **Site Differences: UMASS versus Cordoba** (Table 3)

Patients at both sites displayed the expected differences in TIMI score, age and sex between ACS-negative and ACS-positive groups (data not shown). However, subjects enrolled

1  
2  
3 in Cordoba were significantly younger, with a higher proportion of males and smokers but lower  
4 proportion of diabetics, when compared with UMASS (Table 3). In addition, and as expected  
5 [25], aspirin use was significantly lower among the cohort in Cordoba *versus* the UMASS  
6 population (40% *versus* 80%,  $p < 0.0001$ , Table 3). Despite these demographic differences, a  
7 higher incidence of prolonged closure times in ACS-negative patients was observed at both  
8 sites: i.e., the proportion of subjects with closure times  $\geq 138$  seconds was 13.0% *versus* 10.0%  
9 in ACS-negative groups and 1.9% *versus* 2.0% in ACS-positive patients at UMASS *versus*  
10 Cordoba, respectively.  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Closure time as an independent predictor of diagnosis** (Table 4) 21

22  
23 Logistic regression analysis was first performed with both mandatory variables (closure  
24 time, TIMI risk score) and non-mandatory variables (study site, sex, diabetes, hypertension,  
25 hypercholesterolemia, smoking, clopidogrel use) included in the regression model (data not  
26 shown). ROC analysis revealed that, among the non-mandatory variables, only study site  
27 contributed to an increase to the predictive value of the model for a diagnosis of ACS-negative.  
28 Accordingly, the final multivariate logistic regression model incorporated PFA closure time, TIMI  
29 risk score, and site (UMASS versus Cordoba; Table 4).  
30  
31  
32  
33  
34  
35  
36  
37

38 For every 10-second increase in closure time, the adjusted odds of a diagnosis of ACS-  
39 negative was 1.17 (95% confidence interval: 1.06 to 1.29). That is, when controlling for TIMI risk  
40 score and study site: for every 10 second increase, the prolonged closure time was associated  
41 with a 17% increase in the patient being ACS negative. These results demonstrate that,  
42 *irrespective of TIMI score and site*, closure time was associated with the diagnosis of ACS-  
43 negative, with *closure time providing additional, incremental predictive value beyond that*  
44 *obtained by TIMI score*. The model demonstrated good predictive characteristics ( $c=0.82$ ) and  
45 model fit ( $\chi^2=5.24$ ,  $df=8$ ;  $p=0.73$ ). Finally, the sensitivity analysis that utilized a general  
46 estimating equation accounting for potential correlations among sites did not result in any  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 important changes in the direction of the effects (adjusted odds for every 10 second increase in  
4 closure time: 1.15 with 95% confidence interval 1.10 to 1.23) or conclusions.  
5  
6  
7  
8

## 9 10 **DISCUSSION**

11  
12 In this pilot study, we demonstrate that point-of-care testing of platelet reactivity using  
13 the PFA-100® is feasible in the environment of the ED. Results of our primary analysis revealed  
14 differences in closure times between ACS-negative and ACS-positive cohorts, with the most  
15 notable, discriminating feature being the higher incidence of prolonged closure times in the  
16 ACS-negative group. Finally, the outcome of our multivariate analysis is consistent with the  
17 concept that assessment of closure time provides incremental, independent prognostic value  
18 beyond that obtained using the standard clinical predictor of TIMI score.  
19  
20  
21  
22  
23  
24  
25  
26

### 27 ***Assessment of platelet reactivity as a diagnostic tool for ACS in emergent settings***

28  
29 It is well-established that heightened platelet activity occurs in the setting of ACS [9-11,  
30 13, 14, 26]. Indeed, measurement of platelet reactivity has been utilized in an effort to discern  
31 the stability of coronary disease [10], predict the future incidence and outcomes of major  
32 adverse cardiovascular events [11, 27-31], and, although results have been disappointing, guide  
33 the dosing of anti-platelet agents with the goal of improving outcomes [26, 32, 33]. Our current  
34 study differs from these previous reports, in that it focused on the assessment of platelet  
35 reactivity as an adjunct strategy to risk stratify-patients with potential ACS in emergent  
36 conditions. Accordingly, the novelty of our study lies in our expanded analysis of closure time,  
37 and the identification of a more practical and feasible application of these data in the prognosis  
38 of ACS.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 Our observation of a modest but significant reduction in median/mean closure times in  
52 patients with ACS is consistent with the outcomes of two previous, small ED studies [34, 35].  
53 However, this ~4 second difference is of limited practical significance given the broad and  
54 overlapping distributions of closure times for ACS-negative and ACS-positive cohorts (Figure 2).  
55  
56  
57  
58  
59  
60



1  
2  
3 Rather, we propose ***that the clinical utility of this test lies in the identification of patients***  
4 ***with a prolonged closure time***, a threshold that we objectively defined as the 90<sup>th</sup> percentile of  
5 the distribution of the study population. In this regard, we found that prolonged closure time ( $\geq$ )  
6 138 seconds) had a high specificity and positive predictive value for a diagnosis of ACS-  
7 negative.  
8  
9

### 14 ***Strengths and weaknesses***

16 The results of our pilot study are consistent with the hypothesis that point-of-care testing  
17 of platelet reactivity may assist in the timely rule-out of ACS in the ED. Strengths of this  
18 approach include the fact that assessment of closure time is technically straightforward and  
19 cost-effective, with minimal patient risk (i.e., does not involve exposure to radiation or additional  
20 invasive testing). In addition, our data suggest that the concept is generalizable: the  
21 observation of a higher incidence of prolonged closure times in ACS-negative patients was seen  
22 in subjects from two distinct health care systems and populations (UMASS and Cordoba) that  
23 differ in terms of both demographics and the use of anti-platelet therapy [25].  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 There is, however, an important caveat to this strategy. PFA testing will only contribute  
34 to the identification of a subset of ACS-negative patients, with both the size of the subset and  
35 potential value of the test dependent on the threshold used to define 'prolonged' closure times  
36 (Figure 2 and Table 5). For example, the prospective criterion used in our analysis (the 90<sup>th</sup>  
37 percentile of closure times for all patients enrolled in the study) discerned an arguably modest,  
38 12.4% of ACS-negative patients. However, expediting the discharge of even a small proportion  
39 of patients with a non-cardiac diagnosis would limit the costs, potential risks and patient stress  
40 associated with unneeded advanced diagnostic testing and possibly invasive procedures [1, 2].  
41 Reducing the threshold (i.e., to the 80<sup>th</sup> percentile of the distribution) would increase the size of  
42 the subset identified as ACS-negative, with an accompanying (and increasingly unacceptable)  
43 loss in specificity because of the growing proportion of false-positives (ACS-positive patients  
44 with prolonged closure times: Figure 2 and Table 5). In contrast, increasing the threshold (i.e., to  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 the 95<sup>th</sup> percentile) would identify a diminishing proportion of ACS-negative patients with  
4 increasing specificity (Figure 2 and Table 5). The appropriate definition of 'prolonged' closure  
5 time will therefore require refinement based on risk/benefit analysis.  
6  
7  
8

9  
10 Finally, we emphasize that point-of-case assessment of platelet reactivity and  
11 identification of patients with 'prolonged' closure times clearly cannot function as a stand-alone  
12 test for the rule-out of ACS. Rather, measurement of PFA closure times may serve as an  
13 adjunct to current, standard ED practices. In support of this concept, our multivariate logistic  
14 regression model revealed that, irrespective of TIMI score and study site (and, thus, irrespective  
15 of differences in demographics and aspirin use between sites), closure time was an  
16 independent predictor of the diagnosis of ACS-negative.  
17  
18  
19  
20  
21  
22  
23

#### 24 **Summary, limitations and future directions**

25  
26 We report that measurement of closure time using the PFA-100<sup>®</sup> provides additional and  
27 independent, incremental predictive value in the rule-out of ACS. Limitations of this pilot  
28 feasibility study include the enrollment of patients via convenience sampling, and differences in  
29 the logistics of the chart review process between the two sites. In addition, neither monitoring of  
30 patient outcomes beyond hospital discharge nor risk/benefit analysis of PFA testing was  
31 incorporated into the study design. We emphasize that point-of-care assessment of platelet  
32 reactivity cannot serve as a stand-alone test to either discern ACS-negative *versus* ACS-  
33 positive patients or distinguish among STEMI, NSTEMI and UA in the emergent setting –  
34 limitations that in all likelihood reflect the complex and multi-factorial pathophysiology of acute  
35 myocardial ischemia and infarction. Rather, our results suggest that assessment of closure  
36 times may provide benefit by augmenting standard ED diagnostic practices, a concept that  
37 warrants further large-scale multi-center investigation.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Funding Statement:**

Siemens Inc. provided the Emergency Department at the University of Massachusetts Medical School and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL with PFA-100® devices on a loan basis, as well as partial support for the purchase of test cartridges used in this study.

CED was supported in part by a Research Training Grant from the Society for Academic Emergency Medicine (SAEM), Des Plaines, IL.

The research received no additional, specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interests:** none

**Contributor Statement:**

Conception and design of the study: KP, CED, ADM

Analysis and interpretation of the data: all co-authors

Drafting of the manuscript or revising it critically for important intellectual content: KP, CED, RDW, PW, JASM, CSS, ADM

Final approval of the manuscript: all co-authors

All authors have had full access to all data and take responsibility for the integrity of the data and the accuracy of the analysis. KP is the guarantor.

**Data sharing**

There are no additional unpublished data.

## REFERENCES

1. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: A scientific statement from the American Heart Association. *Circulation*. 2010;**122**:1756-76.
2. Darling CE, Michelson AD, Volturo GA, et al. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. *J Thromb Thrombolysis*. 2009;**28**:31-7.
3. Hollander JE, Chang AM, Shofer FS, et al. Coronary computed tomographic angiography for rapid discharge of low-risk patients with potential acute coronary syndromes. *Ann Emerg Med*. 2009;**53**:295-304.
4. Litt HI, Gatsonis C, Snyder B, et al. Ct angiography for safe discharge of patients with possible acute coronary syndromes. *N Engl J Med*. 2012;**366**:1393-403.
5. Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary ct angiography versus standard evaluation in acute chest pain. *N Engl J Med*. 2012;**367**:299-308.
6. Hoffmann U, Truong QA, Fleg JL, et al. Design of the rule out myocardial ischemia/infarction using computer assisted tomography: A multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. *Am Heart J*. 2012;**163**:330-8, 8 e1.
7. Singer AJ, Domingo A, Thode HC, Jr., et al. Utilization of coronary computed tomography angiography for exclusion of coronary artery disease in ED patients with low- to intermediate-risk chest pain: A 1-year experience. *Am J Emerg Med*. 2012;**30**:1706-11.

- 1  
2  
3 8. Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed  
4 tomography angiography in the emergency department: A systematic review and meta-  
5 analysis of randomized, controlled trials. *J Am Coll Cardiol.* 2013;**61**:880-92.  
6  
7
- 8  
9  
10 9. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute  
11 coronary syndrome: Results from the timi-12 trial. *Thrombolysis in myocardial infarction.*  
12  
13 *J Am Coll Cardiol.* 1999;**33**:634-9.  
14
- 15  
16 10. Linden MD, Furman MI, Frelinger AL, 3rd, et al. Indices of platelet activation and the  
17 stability of coronary artery disease. *J Thromb Haemost.* 2007;**5**:761-5.  
18
- 19  
20 11. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with  
21 coronary artery disease. *J Am Coll Cardiol.* 2007;**50**:1822-34.  
22
- 23  
24 12. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. *J*  
25 *Cardiovasc Pharmacol Ther.* 2009;**14**:157-69.  
26
- 27  
28 13. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. *Nat*  
29 *Rev Drug Discov.* 2010;**9**:154-69.  
30
- 31  
32 14. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. *J Am Coll Cardiol.*  
33  
34 2013;**61**:1-11.  
35
- 36  
37 15. Hollander JE, Muttreja MR, Dalesandro MR, et al. Risk stratification of emergency  
38 department patients with acute coronary syndromes using p-selectin. *J Am Coll Cardiol.*  
39  
40 1999;**34**:95-105.  
41
- 42  
43 16. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating  
44 monocyte-platelet aggregates in patients with stable coronary artery disease. *J Am Coll*  
45 *Cardiol.* 1998;**31**:352-8.  
46
- 47  
48 17. Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of platelet function by flow  
49 cytometry. *Methods.* 2000;**21**:259-70.  
50
- 51  
52 18. Michelson AD. Methods for the measurement of platelet function. *Am J Cardiol.*  
53  
54 2009;**103**:20A-6A.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 **19.** Crescente M, Mezzasoma AM, Del Pinto M, et al. Incomplete inhibition of platelet  
4 function as assessed by the platelet function analyzer (pfa-100) identifies a subset of  
5 cardiovascular patients with high residual platelet response while on aspirin. *Platelets*.  
6 2011;**22**:179-87.  
7
- 8  
9  
10  
11 **20.** Linnemann B, Schwonberg J, Rechner AR, et al. Assessment of clopidogrel non-  
12 response by the pfa-100 system using the new test cartridge innovance pfa p2y. *Ann*  
13 *Hematol*. 2010;**89**:597-605.  
14
- 15  
16  
17 **21.** Poulsen TS, Jorgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients  
18 with an evolving acute myocardial infarction. *Thromb Res*. 2007;**119**:555-62.  
19
- 20  
21  
22 **22.** Poulsen TS, Mickley H, Korsholm L, et al. Using the platelet function analyzer-100 for  
23 monitoring aspirin therapy. *Thromb Res*. 2007;**120**:161-72.  
24
- 25  
26  
27 **23.** Antman EM, Cohen M, Bernink PJ, et al. The timi risk score for unstable angina/non-st  
28 elevation mi: A method for prognostication and therapeutic decision making. *JAMA*.  
29 2000;**284**:835-42.  
30
- 31  
32  
33 **24.** Kelly AM. What is the incidence of major adverse cardiac events in emergency  
34 department chest pain patients with a normal ecg, thrombolysis in myocardial infarction  
35 score of zero and initial troponin <=99th centile: An observational study? *Emerg Med J*.  
36 2013;**30**:15-8.  
37
- 38  
39  
40  
41 **25.** Bernztein RG, Drake I. Use of aspirin in the public primary care level: Experience of the  
42 remediar program, argentina. *Rev Argent Cardiol*. 2010;**78**:330-8.  
43
- 44  
45  
46  
47 **26.** Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for  
48 coronary stenting. *N Engl J Med*. 2012;**367**:2100-9.  
49
- 50  
51  
52  
53 **27.** Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine  
54 diphosphate in patients with stable cardiovascular disease predicts major adverse  
55 events despite antiplatelet therapy. *Platelets*. 2008;**19**:104-10.  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
28. Atiemo AD, Ng'Alla LS, Vaidya D, et al. Abnormal pfa-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. *J Thromb Thrombolysis*. 2008;**25**:173-8.
29. Bevilacqua S, Alkodami AA, Volpi E, et al. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function. *Ann Thorac Surg*. 2009;**87**:496-502.
30. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol*. 2010;**56**:919-33.
31. Breet NJ, van Werkum JW, Bouman HJ, et al. The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a st-elevation myocardial infarction. *Thromb Haemost*. 2011;**106**:331-6.
32. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The gravitas randomized trial. *JAMA*. 2011;**305**:1097-105.
33. Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. *J Am Coll Cardiol*. 2013;**61**.
34. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. *Circulation*. 2004;**110**:1392-7.
35. Harrison P, Mackie I, Mathur A, et al. Platelet hyper-function in acute coronary syndromes. *Blood Coagul Fibrinolysis*. 2005;**16**:557-62.

**FIGURE LEGENDS**

**Figure 1: Inclusion flow-chart.**

**Figure 2: PFA closure time (seconds).** **(A)** Median values with 10<sup>th</sup>, 25<sup>th</sup>, 75<sup>th</sup> and 90<sup>th</sup> percentiles: ACS-positive and ACS-negative cohorts. **(B)** Individual data points for all subjects: ACS-positive and ACS-negative cohorts. Lines denote the 80<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> percentiles of closure times for all patients enrolled in the study. **(C)** Individual data points for all subjects: STEMI, NSTEMI, UA and ACS-negative cohorts. Lines denote the 80<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> percentiles of closure times for all patients enrolled in the study.

**Table 1.**  
**Demographics: All Patients**

	<b>ACS-Negative (total n=330)</b>	<b>ACS-Positive (total n=105)</b>	<b>p-value</b>
Age (years): mean $\pm$ SD	57 $\pm$ 14 (n=328)	61 $\pm$ 13 (n=104)	0.034
Male	65% (n=330)	80% (n=105)	0.004
TIMI score: mean $\pm$ SD	1.9 $\pm$ 1.4 (n=320)	3.1 $\pm$ 1.4 (n=104)	<0.0001
Aspirin	71% (n=321)	64% (n=104)	0.222 (ns)
Clopidogrel	11% (n=325)	20% (n=104)	0.031
Smoker	29% (n=322)	28% (n=105)	0.901(ns)
Hypertension	57% (n=322)	62% (n=105)	0.425 (ns)
Hypercholesterolemia	57% (n=322)	69% (n=105)	0.030
Diabetes	24% (n=322)	27% (n=105)	0.601 (ns)
Family History	40% (n=319)	41% (n=105)	0.909 (ns)



Table 2A.

**Incidence of Prolonged Closure Time**  
 ( $\geq 138$  seconds, defined as the 90<sup>th</sup> percentile of the distribution of the study population)

	ACS-Negative: Yes	ACS-Negative: No	Total
Prolonged closure time: Yes	41	2	43
Prolonged closure time: No	289	103	392
Total	330	105	435

Table 2B.

**Sensitivity, Specificity, Positive and Negative Predictive Values  
 of Prolonged Closure Time for a Diagnosis of ACS-Negative**

Sensitivity	12.4%	95% confidence interval: 9.1% to 16.5%
Specificity	98.1%	95% confidence interval: 93.3% to 99.8%
Positive predictive value	95.4%	95% confidence interval: 84.2% to 99.4%
Negative predictive value	26.3%	95% confidence interval: 22.0% to 30.9%

**Table 3.**  
**Demographics: UMASS vs Cordoba**

	<b>UMASS-All (total n=324)</b>	<b>Cordoba-All (total n=111)</b>	<b>p-value</b>
Age (years): mean $\pm$ SD	59 $\pm$ 14 (n=324)	56 $\pm$ 12 (n=108)	0.036
Male	65% (n=324)	78% (n=111)	0.009
TIMI score: mean $\pm$ SD	2.3 $\pm$ 1.5 (n=313)	2.0 $\pm$ 1.4 (n=111)	0.142 (ns)
Aspirin	80% (n=314)	40% (n=104)	<0.0001
Clopidogrel	15% (n=319)	9% (n=111)	0.146 (ns)
Smoker	26% (n=316)	37% (n=111)	0.038
Hypertension	61% (n=316)	51% (n=111)	0.093 (ns)
Hypercholesterolemia	62% (n=316)	53% (n=111)	0.115 (ns)
Diabetes	28% (n=313)	14% (n=111)	0.005
Family History	44% (n=313)	31% (n=51)	0.014

Table 4.

**Multivariable Logistic Regression Model  
(outcome modeled: ACS-negative)**

<u>Predictor</u>	<u>Adjusted Odds Ratio</u>	<u>95% Confidence Interval</u>
Closure Time	1.17	1.06 to 1.29
TIMI Risk Score	0.48	0.40 to 0.59
Study Site (UMASS <i>versus</i> Cordoba)	7.21	4.05 to 12.86


Table 5.

**Effect of Definition of 'Prolonged' Closure Time on Specificity and Positive Predictive Value for a Diagnosis of ACS-Negative**

Threshold	Specificity	Positive Predictive Value	% of ACS-Negative Patients Identified
<b>95<sup>th</sup> percentile (≥ 160 seconds)</b>	100% [96.6% to 100%]	100% [83.9% to 100%]	6.4% (21/330)
<b>90<sup>th</sup> percentile (≥ 138 seconds)</b>	98.1% [93.3% to 99.8%]	95.4% [84.2% to 99.4%]	12.4% (41/330)
<b>80<sup>th</sup> percentile (≥ 117 seconds)</b>	88.6% [80.9% to 94.0%]	86.2% [77.2% to 92.7%]	22.7% (75/330)

95% confidence intervals shown in square brackets


Figure 1.



191x253mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2.



194x270mm (300 x 300 DPI)



**Point-of-Care Assessment of Platelet Reactivity in the  
Emergency Department May Facilitate Rapid Rule-Out of  
Acute Coronary Syndromes: A Prospective Cohort Pilot  
Feasibility Study**



Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003883.R1
Article Type:	Research
Date Submitted by the Author:	26-Nov-2013
Complete List of Authors:	Darling, Chad; University of Massachusetts Medical School, Emergency Medicine Sala Mercado, Javier; Instituto Modelo de Cardiologia Privado SRL, Quiroga-Castro, Walter; Instituto Modelo de Cardiologia Privado SRL, Tecco, Gabriel; Instituto Modelo de Cardiologia Privado SRL, Zelaya, Felix; Instituto Modelo de Cardiologia Privado SRL, Conci, Eduardo; Instituto Modelo de Cardiologia Privado SRL, Sala, Jose; Instituto Modelo de Cardiologia Privado SRL, Smith, Craig; University of Massachusetts Medical School, Cardiovascular Medicine Michelson, Alan; Harvard Medical School, Whittaker, Peter; Wayne State University School of Medicine, Cardiovascular Research Institute Welch, Rob; Wayne State University, ; Wayne State University School of Medicine, Cardiovascular Research Institute Przyklenk, Karin; Wayne State University School of Medicine, Cardiovascular Research Institute
<b>Primary Subject Heading</b>:	Emergency medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Myocardial infarction < CARDIOLOGY, Adult cardiology < CARDIOLOGY

SCHOLARONE™  
Manuscripts

Word count (excluding title page, abstract, references, figure legends and tables): 3,585

**Point-of-Care Assessment of Platelet Reactivity  
in the Emergency Department  
May Facilitate Rapid Rule-Out of Acute Coronary Syndromes:  
A Prospective Cohort Pilot Feasibility Study**

Chad E. Darling MD\*, Javier A. Sala Mercado MD PhD<sup>§†\*\*</sup>,  
Walter Quiroga-Castro MD\*\*, Gabriel F. Tecco MD\*\*, Felix R. Zelaya MD\*\*,  
Eduardo C. Conci MD\*\*, Jose P. Sala MD\*\*, Craig S. Smith MD<sup>£</sup>,  
Alan D. Michelson MD<sup>†</sup>, Peter Whittaker PhD<sup>\*§¶</sup>, Robert D. Welch MD<sup>§¶</sup>  
and Karin Przyklenk PhD<sup>\*§¶#</sup>

Departments of \*Emergency Medicine and <sup>£</sup> Cardiovascular Medicine,  
University of Massachusetts Medical School,  
Worcester, MA USA

\*\* Division of Cardiology, Instituto Modelo de Cardiologia Privado SRL,  
Cordoba, Argentina

<sup>†</sup> Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital,  
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

<sup>§</sup> Cardiovascular Research Institute and  
Departments of <sup>¶</sup> Emergency Medicine and <sup>‡</sup> Physiology,  
Wayne State University School of Medicine Detroit, MI USA

Short title: Platelet activation and rule-out of ACS

Key words: acute coronary syndromes, platelet, emergency department:

Correspondence: Karin Przyklenk, PhD  
Cardiovascular Research Institute,  
Wayne State University School of Medicine,  
Elliman Building, Room 1107,  
421 E. Canfield,  
Detroit, MI 48201 USA

Telephone: 313-577-9047  
E-mail: [kprzykle@med.wayne.edu](mailto:kprzykle@med.wayne.edu)



**ABSTRACT**

**Objective:** Accurate, efficient and cost-effective disposition of patients presenting to emergency departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS) is a growing priority. Platelet activation is an early feature in the pathogenesis of ACS; thus, we sought to obtain insight into whether point-of-care testing of platelet function: (i) may assist in the rule-out of ACS; (ii) may provide additional predictive value in identifying patients with non-cardiac symptoms *versus* ACS-positive patients; and (iii) is logistically feasible in the ED.

**Design:** Prospective cohort feasibility study.

**Setting:** Two urban tertiary care sites, one located in the United States and the second in Argentina.

**Participants:** 509 adult patients presenting with symptoms of ACS.

**Intervention:** none.

**Main outcome measures:** Platelet reactivity was quantified using the Platelet Function Analyzer (PFA)-100<sup>®</sup>, with closure time (seconds required for blood, aspirated under high shear, to occlude a 150  $\mu$ m aperture) serving as the primary endpoint. Closure times were categorized as 'normal' or 'prolonged', defined objectively as the 90<sup>th</sup> percentile of the distribution for all subjects enrolled in the study. Diagnosis of ACS was made using standard criteria. The use of anti-platelet agents was not an exclusion criterion.

**Results:** Closure times for the study population ranged from 47-300 seconds, with a 90<sup>th</sup> percentile value of 138 seconds. The proportion of patients with closure times  $\geq$ 138 seconds was significantly higher in patients with non-cardiac symptoms (41/330; 12.4%) *versus* the ACS-positive cohort (2/105 [1.9%]; p=0.0006). The specificity of 'prolonged' closure times ( $\geq$  138 seconds) for a diagnosis of non-cardiac symptoms was 98.1%, with a positive predictive power of 95.4%. Multivariate analysis revealed that closure time provided incremental, independent predictive value in the rule-out of ACS.

**Conclusion:** Point-of-care assessment of platelet reactivity is feasible in the ED and may facilitate the rapid rule-out of ACS in patients with prolonged closure times.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Article focus:

- The development of accurate, efficient and cost-effective strategies to assist in the rapid rule-out of acute coronary syndromes (ACS) in the Emergency Department is a growing priority.
- Platelet activation is an early feature in the pathogenesis of ACS.
- Our aims in this pilot feasibility study were to investigate whether point-of-care testing of platelet function, assessed by measuring 'closure time' using the Platelet Function Analyzer (PFA)-100<sup>®</sup>: (i) may assist in the rule-out of ACS; (ii) may provide additional predictive value in identifying patients with non-cardiac symptoms *versus* ACS-positive patients; and (iii) is logistically feasible in the ED.

### Key messages:

- Point-of-care testing of platelet reactivity is feasible in the ED.
- Patients with non-cardiac symptoms *versus* ACS-positive patients were distinguished by differences in the proportion of prolonged closure times.
- Measurement of closure time provided incremental, independent predictive value in the rule-out of ACS.

### Strengths and Limitations:

- The study suggests that a technically straightforward and cost-effective test, with minimal patient risk, may serve as a useful adjunct to current, standard ED practices for the rule-out of ACS. Importantly, the results are generalizable: the observation of a higher incidence of prolonged closure times in patients with non-cardiac symptoms was seen in subjects from two distinct health care systems and populations.

- PFA testing will only contribute to the identification of a subset of patients with non-cardiac symptoms, with both the size of the subset and potential value of the test dependent on the threshold used to define 'prolonged' closure times.
- Limitations of this pilot study include the enrollment of patients via convenience sampling, the fact that patient outcomes were not monitored beyond hospital discharge, and that a risk/benefit analysis was not included in the study design.

For peer review only

1  
2  
3 Accurate, efficient and cost-effective diagnosis of patients presenting to emergency  
4 departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS) – and, in  
5 particular, the exclusion and early discharge of patients with non-cardiac chest pain – is a  
6 growing priority [1, 2]. In an effort to meet this challenge, interest has focused on the  
7 identification of new approaches to augment standard ED procedures and facilitate the timely  
8 triage of patients with suspected ACS. For example, there is recent evidence that coronary CT  
9 angiography (CCTA) combined with routine clinical assessment may provide added prognostic  
10 value in the management of chest pain patients in the ED [3-8]. Use of CCTA in low-to-  
11 intermediate risk patients is reportedly safe and reduces ED costs and hospital length of stay [3-  
12 5, 7, 8]. However, these benefits are accompanied by exposure to radiation and associated  
13 with increases in diagnostic testing and subsequent invasive procedures [5, 8].

14  
15  
16 Assessment of platelet activation, an early feature in the pathogenesis of ACS [9-14],  
17 has also been investigated as a possible benign strategy to expedite the diagnosis of ACS [15,  
18 16]. Application of flow cytometry, the 'gold standard' for the quantitation of molecular indices of  
19 platelet activation, is, however, impractical for routine use under emergent conditions [11, 12,  
20 17, 18]. More importantly, classic molecular indices of platelet activation have not provided  
21 added benefit in the risk stratification of undifferentiated chest pain patients [15, 16].

22  
23 We hypothesized that rapid assessment of platelet reactivity using a technically  
24 straightforward point-of-care device – specifically, the Platelet Function Analyzer (PFA)-100<sup>®</sup>  
25 (Siemens) – may represent a more feasible strategy to assist in the timely rule- out of ACS in  
26 the ED. Rather than quantifying molecular markers of platelet activation-aggregation, the output  
27 of the PFA-100<sup>®</sup> is 'closure time': that is, the time required for whole blood, aspirated under high  
28 shear, to occlude a small, 150 µm aperture in a membrane coated with standard platelet  
29 agonists (collagen-adenosine diphosphate [ADP] or collagen-epinephrine). Although the PFA-  
30 100<sup>®</sup> is typically utilized to investigate the responsiveness of patients to aspirin and other anti-  
31 platelet therapies and aid in the detection of platelet dysfunction [11, 12, 18-22], there is

1  
2  
3 evidence to suggest that shortened closure times may be a marker of the acuity of coronary  
4 disease [10]. Accordingly, our primary aims in this pilot study were to determine whether point-  
5 of-care testing of platelet function: (i) (may assist in the rule-out of ACS; (ii) may yield additional  
6 predictive value in identifying patients with non-cardiac symptoms *versus* ACS-positive patients;  
7 and (iii) is logistically feasible in an emergent setting. In addition, as a secondary analysis, we  
8 investigated whether closure time may be of value in discriminating between ST-elevation  
9 myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)/unstable  
10 angina (UA).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 **METHODS**

25  
26 We conducted a prospective cohort feasibility study of patients presenting with potential  
27 ACS at two urban tertiary care sites: the Emergency Department at the University of  
28 Massachusetts (UMASS)-Memorial Medical Center, University Campus, Worcester, MA USA,  
29 and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL, Cordoba,  
30 Argentina. The enrollment period was from January 2007 to December 2010. At each site,  
31 patients were entered on a convenience basis: i.e., enrollments were not consecutive but,  
32 rather, coincided with the work schedules of the study investigators. The protocol was reviewed  
33 and approved by the respective Institutional Review Boards at both institutions.  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 ***Patient Population***

44  
45 Patients  $\geq 18$  years of age with a potential diagnosis of ACS (at the discretion of the  
46 treating physician and reflected by orders for an electrocardiogram (ECG) and cardiac  
47 biomarkers) were considered for enrollment in the study. Prospective exclusion criteria were  
48 pregnancy, renal insufficiency (defined as serum creatine levels  $\geq 1.5$  mg/dl), anemia  
49 (hematocrit  $< 30\%$ ), platelet count  $< 100,000/\mu\text{L}$ , major bleeding, any gastrointestinal bleeding,  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 trauma, or inability to provide informed consent for any reason. The use of anti-platelet agents  
4  
5 was not an exclusion criterion.  
6

### 7 **Study Enrollment and Protocol**

8  
9  
10 As soon as possible after evaluation by ED staff, potential subjects were approached for  
11  
12 enrollment into the study. If the patient was too ill or otherwise unable to provide written  
13  
14 consent, then proxy consent was attempted. If consent was obtained by proxy and the patient  
15  
16 later became cognizant, they were given the option to continue or withdraw their participation in  
17  
18 the study. If consent was withdrawn, all collected data were discarded.  
19

20  
21 Blood used in the PFA-100<sup>®</sup> was drawn within <1 hour after presentation, at the same  
22  
23 time as cardiac biomarker testing, and closure time was measured within 3 hours of collection.  
24  
25 All samples were obtained via peripheral venipuncture and drawn into tubes containing 3.2%  
26  
27 sodium citrate. Immediately before analysis, each sample was gently inverted; a 900 µL aliquot  
28  
29 of whole blood was then applied to a collagen-ADP test cartridge and closure time was  
30  
31 quantified. Maximum test duration for the PFA-100<sup>®</sup> is 5 minutes; if the aperture is not occluded  
32  
33 within this period, a closure time of '>300 seconds' is displayed.  
34

35  
36 Upon enrollment, patients were questioned regarding a history of bleeding or platelet  
37  
38 function disorders and ingestion of known anti-platelet agents within the past 7 days (aspirin,  
39  
40 clopidogrel, non-steroidal anti-inflammatory agents). In addition, the medical record was  
41  
42 reviewed and standard cardiac risk factors (diabetes, hypertension, hypercholesterolemia,  
43  
44 smoking, family history of heart disease) were recorded and used in the calculation of TIMI risk  
45  
46 score [23].  
47

### 48 **Patient Diagnosis**

49  
50 Final diagnosis (non-cardiac symptoms *versus* ACS-positive) was established via  
51  
52 standardized chart review. All reviews were conducted by physicians in a blinded manner,  
53  
54 without knowledge of the closure time data. For subjects enrolled at the Instituto Modelo de  
55  
56 Cardiologia Privado, patients were seen by a cardiologist at the time of hospital presentation,  
57  
58  
59  
60

1  
2  
3 and all reviews were performed by a team of cardiologists (WQC, GFT, FRZ, ECC, JPS). At  
4  
5 UMASS, each patient was first seen by an Emergency Medicine physician at the time of hospital  
6  
7 presentation, and each chart was reviewed by an ED physician (CED). For patients with a  
8  
9 definitive diagnosis of non-cardiac symptoms (that is, patients with no ischemic ECG changes,  
10  
11 no positive markers or provocative cardiovascular test results, and no history of a diagnosis of  
12  
13 ACS of any type in the chart), no additional review was performed. However, for patients who:  
14  
15 (i) had positive cardiac biomarkers during admission; (ii) underwent cardiac catheterization; (iii)  
16  
17 had a positive provocative cardiovascular test (e.g., exercise stress test); or (iv) had ischemic  
18  
19 ECG changes, the chart was reviewed by both an ED physician and a cardiologist. In any case  
20  
21 in which the diagnosis was uncertain, the decision was adjudicated by a cardiologist (CSS).  
22  
23

24  
25 Patients considered to be ACS-positive were categorized into one of two groups, STEMI  
26  
27 or NSTEMI/UA, in accordance with standard guidelines [24-26]. Patients who did not meet  
28  
29 these criteria were classified as having a diagnosis of non-cardiac chest pain/symptoms.  
30

### 31 **Statistical Analysis**

32  
33 Our target sample size in this exploratory study was empiric. We reasoned that, as an  
34  
35 approximate order of magnitude, ~100 patients would be required in the ACS-positive group in  
36  
37 order to have a likelihood of discerning a potential difference in closure times between patients  
38  
39 with non-cardiac symptoms and the ACS-positive cohort. Assuming that 75% of patients  
40  
41 enrolled in the study would have a diagnosis of non-cardiac chest pain (and thus 25% would be  
42  
43 ACS-positive), a total of approximately 400 patients would be required. To account for  
44  
45 exclusions, target enrollment was set at ~500 subjects.  
46  
47

### 48 Univariate comparisons

49  
50 Our primary analyses focused on the comparison of patients in the two main outcome  
51  
52 groups: non-cardiac symptoms *versus* ACS-positive. All categorical data were compared using  
53  
54 the Fisher's Exact Test and are reported as percentages. For continuous data, the D'Agostino  
55  
56 and Pearson Test was applied to determine normality and the appropriate parametric (t-test) or  
57  
58  
59  
60



1  
2  
3 non-parametric alternative (Mann-Whitney) tests were utilized. Secondary analysis (comparison  
4 of closure times among non-cardiac chest pain, STEMI and NSTEMI/UA groups) was  
5  
6 of closure times among non-cardiac chest pain, STEMI and NSTEMI/UA groups) was  
7  
8 conducted using the Kruskal-Wallis test. Results are reported as mean  $\pm$  standard deviation or  
9  
10 medians with associated 10<sup>th</sup> and 90<sup>th</sup> percentile ranges.

### 11 Sensitivity, specificity and multivariate analysis

12  
13  
14 We made the prospective and arbitrary decision to categorize closure time into “normal”  
15  
16 and “prolonged” values based on the 90<sup>th</sup> percentile of the distribution for all patients enrolled in  
17  
18 the study. Utilizing the normal and prolonged values of closure time, the sensitivity, specificity,  
19  
20 negative and positive predictive values and likelihood ratio for identifying patients with **non-**  
21  
22 **cardiac symptoms** were determined. Two reasons contributed to our choice of non-cardiac  
23  
24 chest pain (rather than ACS positive) as the main outcome of interest: (i) this approach is  
25  
26 consistent with current guidelines for the improvement of diagnostic accuracy [1, 8]; and (ii) we  
27  
28 reasoned that prolonged closure times may be associated with the absence of ACS, whereas  
29  
30 shorter closure times may be manifest in either group of patients. Sensitivity, specificity,  
31  
32 predictive values and the likelihood ratio are reported with associated 95% confidence intervals.  
33  
34

35  
36 To determine if PFA closure time provides additional predictive value to standard clinical  
37  
38 diagnostic information, a logistic regression was developed to assess its independent  
39  
40 association with the main outcome of non-cardiac symptoms. Independent predictor variables  
41  
42 considered to be mandatory in the model were closure time (utilizing continuous rather than the  
43  
44 categorized values; the main predictor of interest) and the TIMI risk score (representing  
45  
46 standard clinical information to predict ACS outcomes). To account for potential differences  
47  
48 between UMASS and Cordoba, study site was also added to the regression model. Other non-  
49  
50 mandatory variables considered for inclusion were sex, a medical history of diabetes,  
51  
52 hypertension, hypercholesterolemia, smoking, and clopidogrel use. As age and aspirin use are  
53  
54 individually incorporated in the TIMI risk score, these variables were not considered for separate  
55  
56 inclusion in the model. Non-mandatory variables were left in the model only if they yielded an  
57  
58  
59  
60

1  
2  
3 increase in predictive value as determined by ROC (receiver operating characteristic) analysis  
4  
5 or were of additional importance based on the 2 log likelihood ratio test.  
6

7  
8 The reported estimate and adjusted odds ratio for closure time were calculated for an  
9  
10 increase in platelet closure time of 10 seconds (rather than 1 second), a choice based on the  
11  
12 premise that a 1-second increase would be of limited clinical usefulness. The final model was  
13  
14 evaluated by c-statistic (area under the ROC curve) and the Hosmer and Lemeshow fit test. As  
15  
16 a sensitivity test, the results were calculated using the general estimating equation (PROC  
17  
18 GENMOD) with study site evaluated as a subject factor (cluster) rather than a term in the model.  
19  
20 The Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI) statistic  
21  
22 were not included in the analyses, given the skepticism and criticisms that have been raised  
23  
24 concerning their value in predicting the potential, incremental prognostic impact of novel  
25  
26 biomarkers [27, 28].  
27  
28

29  
30 Analyses were performed using GraphPad Prism Version 5.04 (San Diego CA) and  
31  
32 SAS Version 9.3, (Carey NC).  
33  
34  
35

## 36 RESULTS

### 37 ***Enrollment and exclusions*** (Figure 1)

38  
39 A combined total of 509 patients were enrolled at the two study sites. Sixty-one subjects  
40  
41 were excluded because closure time data were not available: reasons included technical errors  
42  
43 (n=14), closure times >300 seconds (possibly due to mild thrombocytopenia, anemia, or  
44  
45 inadequate mixing of the blood sample prior to testing; n=36), and failure to measure closure  
46  
47 time despite obtaining consent (n=11). An additional 5 subjects were removed from analysis  
48  
49 because exclusion criteria were identified after consent was obtained (n=4), or consent was  
50  
51 revoked after the blood sample was collected (n=1). For the remaining 443 patients in whom  
52  
53 closure time was quantified, 8 were diagnosed with thrombotic events that were non-cardiac in  
54  
55 origin and thus were excluded from further analysis. Accordingly, results are reported for 435  
56  
57  
58  
59  
60

1  
2  
3 subjects (324 enrolled at UMASS and 111 enrolled in Cordoba): 105 were diagnosed with ACS  
4  
5 and 330 had non-cardiac symptoms.  
6

7  
8 **Demographics** (Table 1)  
9

10 As expected [29], the ACS-positive group had higher TIMI scores, was older, and had a  
11 higher proportion of male subjects *versus* patients with non-cardiac symptoms. In addition, the  
12 incidence of hypercholesterolemia and use of clopidogrel were significantly higher in the ACS  
13 group. There were, however, no differences in the use of aspirin, incidence of hypertension or  
14 diabetes, proportion of smokers or reported family history of heart disease between the two  
15 groups.  
16  
17  
18  
19  
20  
21

22  
23 **Closure time** (Figure 2 and Table 2)  
24

25 There was a modest but significant difference in median closure times in patients with  
26 non-cardiac symptoms *versus* the ACS-positive group: 91 *versus* 87 seconds, respectively  
27 ( $p=0.0061$ ; Figure 2A). When the ACS-positive group was divided into STEMI and combined  
28 NSTEMI/UA cohorts, the modest differences in closure time in the secondary 3-group analysis  
29 remained significant ( $p=0.0001$ ; Figure 2C).  
30  
31  
32  
33  
34

35 Of potentially greater importance, patients with non-cardiac symptoms *versus* ACS-  
36 positive patients were distinguished by differences in the proportion of prolonged closure times.  
37 We found that 41/330 (12.4%) of patients with non-cardiac symptoms had closure times  $\geq 138$   
38 seconds (i.e., the 90<sup>th</sup> percentile of the distribution for all patients enrolled in the study) while, in  
39 contrast, 2/105 (1.9%) of patients in the ACS-positive group had closure times  $\geq$  this value  
40 ( $p=0.0006$ ; Figure 2B and Table 2A). The specificity and sensitivity of 'prolonged' closure times  
41 ( $\geq 138$  seconds) for a diagnosis of non-cardiac symptoms were 98.1% and 12.4%, respectively,  
42 with positive a positive predictive value of 95.4%, negative predictive value of 26.3%, and  
43 likelihood ratio of 6.52 (Table 2B).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Site Differences: UMASS versus Cordoba** (Table 3)

Patients at both sites displayed the expected differences in TIMI score, age and sex between non-cardiac chest pain and ACS-positive groups (data not shown). However, subjects enrolled in Cordoba were significantly younger, with a higher proportion of males and smokers but lower proportion of diabetics, when compared with UMASS (Table 3). In addition, and as expected [30, 31], aspirin use was significantly lower among the cohort in Cordoba *versus* the UMASS population (40% *versus* 80%,  $p < 0.0001$ , Table 3). Despite these demographic differences, a higher incidence of prolonged closure times in patients with non-cardiac symptoms was observed at both sites: i.e., the proportion of subjects with closure times  $\geq 138$  seconds was 13.0% *versus* 10.0% in patients with non-cardiac chest pain and 1.9% *versus* 2.0% in ACS-positive patients at UMASS *versus* Cordoba, respectively.

**Closure time as an independent predictor of diagnosis** (Table 4)

Logistic regression analysis was first performed with both mandatory variables (closure time, TIMI risk score) and non-mandatory variables (study site, sex, diabetes, hypertension, hypercholesterolemia, smoking, clopidogrel use) included in the regression model (data not shown). ROC analysis revealed that, among the non-mandatory variables, only study site (UMASS *versus* Cordoba) contributed to an increase to the predictive value of the model for a diagnosis of non-cardiac symptoms. Comparison of ROC curves obtained by including closure time, TIMI score and site in the model *versus* TIMI score and site alone showed a significant, incremental increase in area under the curve with the addition of closure time (0.818 *versus* 0.795;  $p = 0.009$ ; Figure 3). Accordingly, the final multivariate logistic regression model incorporated these three variables (Table 4).

For every 10-second increase in closure time, the adjusted odds of a diagnosis of non-cardiac symptoms was 1.17 (95% confidence interval: 1.06 to 1.29). That is, when controlling for TIMI risk score and study site: for every 10 second increase, the prolonged closure time was associated with a 17% increase in the patient having non-cardiac chest pain. These results

1  
2  
3 demonstrate that, *irrespective of TIMI score and site*, closure time was associated with the  
4 diagnosis of non-cardiac symptoms, with *closure time providing additional, incremental*  
5 *predictive value beyond that obtained by TIMI score*. The model demonstrated good predictive  
6 characteristics ( $c=0.82$ ) and model fit ( $\chi^2=5.24$ ,  $df=8$ ;  $p=0.73$ ). Finally, the sensitivity analysis  
7 that utilized a general estimating equation accounting for potential correlations among sites did  
8 not result in any important changes in the direction of the effects (adjusted odds for every 10  
9 second increase in closure time: 1.15 with 95% confidence interval 1.10 to 1.23) or  
10 conclusions.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

## 23 DISCUSSION

24  
25 In this study, we demonstrate that point-of-care testing of platelet reactivity using the  
26 PFA-100<sup>®</sup> is feasible in the environment of the ED. Results of our primary analysis revealed  
27 differences in closure times between patients with non-cardiac symptoms *versus* ACS-positive  
28 cohorts, with the most notable, discriminating feature being the higher incidence of prolonged  
29 closure times in the group with non-cardiac chest pain. Finally, the outcome of our multivariate  
30 analysis is consistent with the concept that assessment of closure time provides incremental,  
31 independent prognostic value beyond that obtained using the standard clinical predictor of TIMI  
32 score.  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 ***Assessment of platelet reactivity as a diagnostic tool for ACS in emergent settings***

43  
44 It is well-established that heightened platelet activity occurs in the setting of ACS [9-11,  
45 13, 14, 32]. Indeed, measurement of platelet reactivity has been utilized in an effort to discern  
46 the stability of coronary disease [10], predict the future incidence and outcomes of major  
47 adverse cardiovascular events [11, 33-37], and, although results have been disappointing, guide  
48 the dosing of anti-platelet agents with the goal of improving outcomes [32, 38, 39]. Our current  
49 study differs from these previous reports, in that it focused on the assessment of platelet  
50 reactivity as an adjunct strategy to risk stratify-patients with potential ACS in emergent  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 conditions. Accordingly, the novelty of our study lies in our expanded analysis of closure time,  
4  
5 and the identification of a more practical and feasible application of these data in the prognosis  
6  
7 of ACS.  
8

9  
10 Our observation of a modest but significant reduction in median/mean closure times in  
11  
12 patients with ACS is consistent with the outcomes of two previous, small ED studies [40, 41].  
13  
14 However, this ~4 second difference is of limited practical significance given the broad and  
15  
16 overlapping distributions of closure times for patients with non-cardiac symptoms and the ACS-  
17  
18 positive cohort (Figure 2). Rather, we propose **that the clinical utility of this test lies in the**  
19  
20 **identification of patients with a prolonged closure time**, a threshold that we objectively  
21  
22 defined as the 90<sup>th</sup> percentile of the distribution of the study population. In this regard, we found  
23  
24 that prolonged closure time ( $\geq 138$  seconds) had a high specificity, positive predictive value and  
25  
26 likelihood ratio for a diagnosis of non-cardiac chest pain.  
27  
28

### 29 **Strengths and weaknesses**

30  
31 The results of our pilot study are consistent with the hypothesis that point-of-care testing  
32  
33 of platelet reactivity may assist in the timely rule-out of ACS in the ED. Strengths of this  
34  
35 approach include the fact that assessment of closure time is technically straightforward and  
36  
37 cost-effective, with minimal patient risk (i.e., does not involve exposure to radiation or additional  
38  
39 invasive testing). In addition, our data suggest that the concept is generalizable. We observed  
40  
41 significant differences in demographics (age and gender), the prevalence of specific risk factors  
42  
43 (diabetes, smoking) and the use of anti-platelet therapy (aspirin: Table 3) between UMASS and  
44  
45 Cordoba – findings that are in agreement with published reports focused on Argentine cohorts  
46  
47 [30, 31, 42], and may underlie the robust contribution of study site as a predictor of outcome in  
48  
49 our logistic regression model. Nonetheless, our results, obtained from two distinct health care  
50  
51 systems and populations, consistently revealed a higher proportion of prolonged closure times  
52  
53 in patients with non-cardiac symptoms.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There is, however, an important caveat to this strategy. PFA testing will only contribute to the identification of a subset of patients with non-cardiac symptoms, with both the size of the subset and potential value of the test dependent on the threshold used to define 'prolonged' closure times (Figure 2 and Table 5). For example, the prospective and arbitrary criterion used in our analysis (the 90<sup>th</sup> percentile of closure times for all patients enrolled in the study) discerned an arguably modest, 12.4% of patients with a diagnosis of non-cardiac symptoms. However, expediting the discharge of even a small proportion of patients with a non-cardiac diagnosis would limit the costs, potential risks and patient stress associated with unneeded advanced diagnostic testing and possibly invasive procedures [1, 2]. Reducing the threshold (i.e., to the 80<sup>th</sup> percentile of the distribution) would increase the size of the subset identified as ACS-negative, with an accompanying (and increasingly unacceptable) loss in specificity because of the growing proportion of false-positives (ACS-positive patients with prolonged closure times: Figure 2 and Table 5). In contrast, increasing the threshold (i.e., to the 95<sup>th</sup> percentile) would identify a diminishing proportion of patients with non-cardiac symptoms with increasing specificity (Figure 2 and Table 5). The appropriate definition of 'prolonged' closure time will therefore require refinement based on risk/benefit analysis.

Finally, we emphasize that point-of-case assessment of platelet reactivity and identification of patients with 'prolonged' closure times clearly cannot function as a stand-alone test for the rule-out of ACS. Rather, measurement of PFA closure times may serve as an adjunct to current, standard ED practices. In support of this concept, our multivariate logistic regression model revealed that, irrespective of TIMI score and study site (and, thus, irrespective of differences in demographics and aspirin use between sites), closure time was an independent predictor of the diagnosis of non-cardiac symptoms.

### ***Summary, limitations and future directions***

We report that measurement of closure time using the PFA-100<sup>®</sup> provides additional and independent, incremental predictive value in the rule-out of ACS. Limitations of this pilot



1  
2  
3 feasibility study include the enrollment of patients via convenience sampling, and differences in  
4 the logistics of the chart review process between the two sites. In addition, neither monitoring of  
5 patient outcomes beyond hospital discharge (raising the possibility of potential misclassification  
6 of some patients) nor risk/benefit analysis of PFA testing was incorporated into the study  
7 design. We emphasize that point-of-care assessment of platelet reactivity cannot serve as a  
8 stand-alone test to either discern patients with non-cardiac symptoms *versus* ACS-positive  
9 patients or distinguish between STEMI versus NSTEMI/UA in the emergent setting – limitations  
10 that in all likelihood reflect the complex and multi-factorial pathophysiology of acute myocardial  
11 ischemia and infarction. Rather, our results suggest that assessment of closure times may  
12 provide benefit by augmenting standard ED diagnostic practices, a concept that warrants further  
13 large-scale multi-center investigation.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Funding Statement:**

Siemens Inc. provided the Emergency Department at the University of Massachusetts Medical School and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL with PFA-100<sup>®</sup> devices on a loan basis, as well as partial support for the purchase of test cartridges used in this study.

CED was supported in part by a Research Training Grant from the Society for Academic Emergency Medicine (SAEM), Des Plaines, IL.

The research received no additional, specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interests:** none

**Contributor Statement:**

Conception and design of the study: KP, CED, ADM

Analysis and interpretation of the data: all co-authors

Drafting of the manuscript or revising it critically for important intellectual content: KP, CED, RDW, PW, JASM, CSS, ADM

Final approval of the manuscript: all co-authors

All authors have had full access to all data and take responsibility for the integrity of the data and the accuracy of the analysis. KP is the guarantor.

## REFERENCES

1. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. *Circulation*. 2010;**122**:1756-76.
2. Darling CE, Michelson AD, Volturo GA, et al. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. *J Thromb Thrombolysis*. 2009;**28**:31-7.
3. Hollander JE, Chang AM, Shofer FS, et al. Coronary computed tomographic angiography for rapid discharge of low-risk patients with potential acute coronary syndromes. *Ann Emerg Med*. 2009;**53**:295-304.
4. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. *N Engl J Med*. 2012;**366**:1393-403.
5. Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. *N Engl J Med*. 2012;**367**:299-308.
6. Hoffmann U, Truong QA, Fleg JL, et al. Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. *Am Heart J*. 2012;**163**:330-8, 8 e1.
7. Singer AJ, Domingo A, Thode HC, Jr., et al. Utilization of coronary computed tomography angiography for exclusion of coronary artery disease in ED patients with low- to intermediate-risk chest pain: a 1-year experience. *Am J Emerg Med*. 2012;**30**:1706-11.

- 1  
2  
3 8. Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed  
4 tomography angiography in the emergency department: a systematic review and meta-  
5 analysis of randomized, controlled trials. *J Am Coll Cardiol.* 2013;**61**:880-92.  
6  
7
- 8  
9 9. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute  
10 coronary syndrome: results from the TIMI-12 trial. *Thrombolysis in Myocardial Infarction.*  
11  
12 *J Am Coll Cardiol.* 1999;**33**:634-9.  
13  
14
- 15 10. Linden MD, Furman MI, Frelinger AL, 3rd, et al. Indices of platelet activation and the  
16 stability of coronary artery disease. *J Thromb Haemost.* 2007;**5**:761-5.  
17  
18
- 19 11. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with  
20 coronary artery disease. *J Am Coll Cardiol.* 2007;**50**:1822-34.  
21  
22
- 23 12. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. *J*  
24 *Cardiovasc Pharmacol Ther.* 2009;**14**:157-69.  
25  
26
- 27 13. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. *Nat*  
28 *Rev Drug Discov.* 2010;**9**:154-69.  
29  
30
- 31 14. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. *J Am Coll Cardiol.*  
32 2013;**61**:1-11.  
33  
34
- 35 15. Hollander JE, Muttreja MR, Dalesandro MR, et al. Risk stratification of emergency  
36 department patients with acute coronary syndromes using P-selectin. *J Am Coll Cardiol.*  
37 1999;**34**:95-105.  
38  
39
- 40 16. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating  
41 monocyte-platelet aggregates in patients with stable coronary artery disease. *J Am Coll*  
42 *Cardiol.* 1998;**31**:352-8.  
43  
44
- 45 17. Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of platelet function by flow  
46 cytometry. *Methods.* 2000;**21**:259-70.  
47  
48
- 49 18. Michelson AD. Methods for the measurement of platelet function. *Am J Cardiol.*  
50 2009;**103**:20A-6A.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
19. Crescente M, Mezzasoma AM, Del Pinto M, et al. Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. *Platelets*. 2011;**22**:179-87.
  20. Linnemann B, Schwonberg J, Rechner AR, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. *Ann Hematol*. 2010;**89**:597-605.
  21. Poulsen TS, Jorgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. *Thromb Res*. 2007;**119**:555-62.
  22. Poulsen TS, Mickley H, Korsholm L, et al. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. *Thromb Res*. 2007;**120**:161-72.
  23. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. *JAMA*. 2000;**284**:835-42.
  24. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;**127**:529-55.
  25. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Circulation*. 2012;**126**:2020-35.
  26. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;**127**:e663-828.

- 1  
2  
3 **27.** Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on  
4 integrated discrimination improvement and net reclassification index. *Stat Med.* 2013:  
5  
6  
7 Epub 5 April 2013.
- 8  
9 **28.** Kerr KF, Wang Z, Janes H, et al. Net reclassification indices for evaluating risk prediction  
10 instruments: a critical review. *Epidemiology.* 2013: Epub 14 November, 2013.
- 11  
12  
13 **29.** Kelly AM. What is the incidence of major adverse cardiac events in emergency  
14 department chest pain patients with a normal ECG, Thrombolysis in Myocardial  
15 Infarction score of zero and initial troponin  $\leq$ 99th centile: an observational study?  
16  
17  
18  
19  
20  
21  
22 *Emerg Med J.* 2013;**30**:15-8.
- 23 **30.** Bernardi V, Szarfer J, Summay G, et al. Long-term versus short-term clopidogrel therapy  
24 in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel  
25 Stent [RACS] trial). *Am J Cardiol.* 2007;**99**:349-52.
- 26  
27  
28 **31.** Bernztein RG, Drake I. Use of aspirin in the public primary care level: experience of the  
29 Remediar Program, Argentina. *Rev Argent Cardiol.* 2010;**78**:330-8.
- 30  
31  
32 **32.** Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for  
33 coronary stenting. *N Engl J Med.* 2012;**367**:2100-9.
- 34  
35  
36  
37 **33.** Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine  
38 diphosphate in patients with stable cardiovascular disease predicts major adverse  
39 events despite antiplatelet therapy. *Platelets.* 2008;**19**:104-10.
- 40  
41  
42  
43  
44 **34.** Atiemo AD, Ng'Alla LS, Vaidya D, et al. Abnormal PFA-100 closure time is associated  
45 with increased platelet aggregation in patients presenting with chest pain. *J Thromb*  
46  
47  
48  
49  
50 *Thrombolysis.* 2008;**25**:173-8.
- 51 **35.** Bevilacqua S, Alkodami AA, Volpi E, et al. Risk stratification after coronary artery bypass  
52 surgery by a point-of-care test of platelet function. *Ann Thorac Surg.* 2009;**87**:496-502.
- 53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
36. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol*. 2010;**56**:919-33.
37. Breet NJ, van Werkum JW, Bouman HJ, et al. The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction. *Thromb Haemost*. 2011;**106**:331-6.
38. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA*. 2011;**305**:1097-105.
39. Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. *J Am Coll Cardiol*. 2013;**61**.
40. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. *Circulation*. 2004;**110**:1392-7.
41. Harrison P, Mackie I, Mathur A, et al. Platelet hyper-function in acute coronary syndromes. *Blood Coagul Fibrinolysis*. 2005;**16**:557-62.
42. Moran A, Degennaro V, Ferrante D, et al. Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: the Coronary Heart Disease Policy Model. *Int J Cardiol*. 2011;**150**:332-7.

## FIGURE LEGENDS

**Figure 1: Inclusion flow-chart.**

**Figure 2: PFA closure time (seconds).** (A) Median values with 10<sup>th</sup>, 25<sup>th</sup>, 75<sup>th</sup> and 90<sup>th</sup> percentiles: ACS-positive patients and patients with non-cardiac symptoms. (B) Individual data points for all subjects: ACS-positive patients and patients with non-cardiac symptoms. Lines denote the 80<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> percentiles of closure times for all patients enrolled in the study. (C) Individual data points for all subjects: STEMI, NSTEMI/UA cohorts and patients with non-cardiac symptoms. Lines denote the 80<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> percentiles of closure times for all patients enrolled in the study.

**Figure 3: ROC analysis.** Comparison of ROC curves obtained by including closure time, TIMI score and study site in the regression model *versus* TIMI score and site alone showed a significant, incremental increase in area under the curve with the addition of closure time (0.818 *versus* 0.795; p=0.009).

**Table 1.**  
**Demographics: All Patients**

	<b>Non-Cardiac Symptoms (total n=330)</b>	<b>ACS-Positive (total n=105)</b>	<b>p-value</b>
Age (years): mean $\pm$ SD	57 $\pm$ 14 (n=328)	61 $\pm$ 13 (n=104)	0.034
Male	65% (n=330)	80% (n=105)	0.004
TIMI score: mean $\pm$ SD	1.9 $\pm$ 1.4 (n=320)	3.1 $\pm$ 1.4 (n=104)	<0.0001
Aspirin	71% (n=321)	64% (n=104)	0.222 (ns)
Clopidogrel	11% (n=325)	20% (n=104)	0.031
Smoker	29% (n=322)	28% (n=105)	0.901 (ns)
Hypertension	57% (n=322)	62% (n=105)	0.425 (ns)
Hypercholesterolemia	57% (n=322)	69% (n=105)	0.030
Diabetes	24% (n=322)	27% (n=105)	0.601 (ns)
Family History	40% (n=319)	41% (n=105)	0.909 (ns)



Table 2A.

**Incidence of Prolonged Closure Time**  
 ( $\geq 138$  seconds, defined as the 90<sup>th</sup> percentile of the distribution of the study population)

	<b>Non-Cardiac Symptoms</b>	<b>ACS-Positive</b>	<b>Total</b>
<b>Prolonged closure time: Yes</b>	41	2	43
<b>Prolonged closure time: No</b>	289	103	392
<b>Total</b>	330	105	435

Table 2B.

**Sensitivity, Specificity, Positive and Negative Predictive Values and Likelihood Ratio of Prolonged Closure Time for a Diagnosis of Non-Cardiac Symptoms**

Sensitivity	12.4%	95% confidence interval: 9.1% to 16.5%
Specificity	98.1%	95% confidence interval: 93.3% to 99.8%
Positive predictive value	95.4%	95% confidence interval: 84.2% to 99.4%
Negative predictive value	26.3%	95% confidence interval: 22.0% to 30.9%
Likelihood ratio:	6.52	95% confidence interval: 1.61 to 26.51

**Table 3.**  
**Demographics: UMASS vs Cordoba**

	<b>UMASS-All (total n=324)</b>	<b>Cordoba-All (total n=111)</b>	<b>p-value</b>
Age (years): mean $\pm$ SD	59 $\pm$ 14 (n=324)	56 $\pm$ 12 (n=108)	0.036
Male	65% (n=324)	78% (n=111)	0.009
TIMI score: mean $\pm$ SD	2.3 $\pm$ 1.5 (n=313)	2.0 $\pm$ 1.4 (n=111)	0.142 (ns)
Aspirin	80% (n=314)	40% (n=104)	<0.0001
Clopidogrel	15% (n=319)	9% (n=111)	0.146 (ns)
Smoker	26% (n=316)	37% (n=111)	0.038
Hypertension	61% (n=316)	51% (n=111)	0.093 (ns)
Hypercholesterolemia	62% (n=316)	53% (n=111)	0.115 (ns)
Diabetes	28% (n=313)	14% (n=111)	0.005
Family History	44% (n=313)	31% (n=51)	0.014

Table 4.

**Multivariable Logistic Regression Model  
(outcome modeled: Non-Cardiac Symptoms)**

<b><u>Predictor</u></b>	<b><u>Adjusted Odds Ratio</u></b>	<b><u>95% Confidence Interval</u></b>
Closure Time	1.17	1.06 to 1.29
TIMI Risk Score	0.48	0.40 to 0.59
Study Site (UMASS <i>versus</i> Cordoba)	7.21	4.05 to 12.86

Table 5.

**Effect of Definition of 'Prolonged' Closure Time on Specificity and Positive Predictive Value for a Diagnosis of Non-Cardiac Symptoms**

Threshold	Specificity	Positive Predictive Value	% of Patients with Non-Cardiac Symptoms Identified
<b>95<sup>th</sup> percentile (≥ 160 seconds)</b>	100% [96.6% to 100%]	100% [83.9% to 100%]	6.4% (21/330)
<b>90<sup>th</sup> percentile (≥ 138 seconds)</b>	98.1% [93.3% to 99.8%]	95.4% [84.2% to 99.4%]	12.4% (41/330)
<b>80<sup>th</sup> percentile (≥ 117 seconds)</b>	88.6% [80.9% to 94.0%]	86.2% [77.2% to 92.7%]	22.7% (75/330)

95% confidence intervals shown in square brackets

Word count (excluding title page, abstract, references, figure legends and tables): 3,585

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Point-of-Care Assessment of Platelet Reactivity in the Emergency Department May Facilitate Rapid Rule-Out of Acute Coronary Syndromes: A Prospective Cohort Pilot Feasibility Study

Chad E. Darling MD\*, Javier A. Sala Mercado MD PhD<sup>§†\*\*</sup>,  
Walter Quiroga-Castro MD\*\*, Gabriel F. Tecco MD\*\*, Felix R. Zelaya MD\*\*,  
Eduardo C. Conci MD\*\*, Jose P. Sala MD\*\*, Craig S. Smith MD<sup>£</sup>,  
Alan D. Michelson MD<sup>†</sup>, Peter Whittaker PhD\*<sup>§¶</sup>, Robert D. Welch MD<sup>§¶</sup>  
and Karin Przyklenk PhD\*<sup>§¶#</sup>

Departments of \*Emergency Medicine and <sup>£</sup> Cardiovascular Medicine,  
University of Massachusetts Medical School,  
Worcester, MA USA

\*\* Division of Cardiology, Instituto Modelo de Cardiologia Privado SRL,  
Cordoba, Argentina

<sup>†</sup> Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital,  
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

<sup>§</sup> Cardiovascular Research Institute and  
Departments of <sup>¶</sup> Emergency Medicine and <sup>‡</sup> Physiology,  
Wayne State University School of Medicine Detroit, MI USA

Short title: Platelet activation and rule-out of ACS

Key words: acute coronary syndromes, platelet, emergency department:

Correspondence: Karin Przyklenk, PhD  
Cardiovascular Research Institute,  
Wayne State University School of Medicine,  
Elliman Building, Room 1107,  
421 E. Canfield,  
Detroit, MI 48201 USA

Telephone: 313-577-9047  
E-mail: [kprzykle@med.wayne.edu](mailto:kprzykle@med.wayne.edu)

**ABSTRACT**

**Objective:** Accurate, efficient and cost-effective disposition of patients presenting to emergency departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS) is a growing priority. Platelet activation is an early feature in the pathogenesis of ACS; thus, we sought to obtain insight into whether point-of-care testing of platelet function: (i) may assist in the rule-out of ACS; (ii) may provide additional predictive value in identifying patients with non-cardiac symptoms *versus* ACS-positive patients; and (iii) is logistically feasible in the ED.

**Design:** Prospective cohort feasibility study.

**Setting:** Two urban tertiary care sites, one located in the United States and the second in Argentina.

**Participants:** 509 adult patients presenting with symptoms of ACS.

**Intervention:** none.

**Main outcome measures:** Platelet reactivity was quantified using the Platelet Function Analyzer (PFA)-100<sup>®</sup>, with closure time (seconds required for blood, aspirated under high shear, to occlude a 150 µm aperture) serving as the primary endpoint. Closure times were categorized as 'normal' or 'prolonged', defined objectively as the 90<sup>th</sup> percentile of the distribution for all subjects enrolled in the study. Diagnosis of ACS was made using standard criteria. The use of anti-platelet agents was not an exclusion criterion.

**Results:** Closure times for the study population ranged from 47-300 seconds, with a 90<sup>th</sup> percentile value of 138 seconds. The proportion of patients with closure times  $\geq 138$  seconds was significantly higher in patients with non-cardiac symptoms (41/330; 12.4%) *versus* the ACS-positive cohort (2/105 [1.9%];  $p=0.0006$ ). The specificity of 'prolonged' closure times ( $\geq 138$  seconds) for a diagnosis of non-cardiac symptoms was 98.1%, with a positive predictive power of 95.4%. Multivariate analysis revealed that closure time provided incremental, independent predictive value in the rule-out of ACS.

1  
2  
3 **Conclusion:** Point-of-care assessment of platelet reactivity is feasible in the ED and may  
4  
5 facilitate the rapid rule-out of ACS in patients with prolonged closure times.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Article focus:

- The development of accurate, efficient and cost-effective strategies to assist in the rapid rule-out of acute coronary syndromes (ACS) in the Emergency Department is a growing priority.
- Platelet activation is an early feature in the pathogenesis of ACS.
- Our aims in this pilot feasibility study were to investigate whether point-of-care testing of platelet function, assessed by measuring 'closure time' using the Platelet Function Analyzer (PFA)-100<sup>®</sup>: (i) may assist in the rule-out of ACS; (ii) may provide additional predictive value in identifying patients with non-cardiac symptoms *versus* ACS-positive patients; and (iii) is logistically feasible in the ED.

### Key messages:

- Point-of-care testing of platelet reactivity is feasible in the ED.
- Patients with non-cardiac symptoms *versus* ACS-positive patients were distinguished by differences in the proportion of prolonged closure times.
- Measurement of closure time provided incremental, independent predictive value in the rule-out of ACS.

### Strengths and Limitations:

- The study suggests that a technically straightforward and cost-effective test, with minimal patient risk, may serve as a useful adjunct to current, standard ED practices for the rule-out of ACS. Importantly, the results are generalizable: the observation of a higher incidence of prolonged closure times in patients with non-cardiac symptoms was seen in subjects from two distinct health care systems and populations.



- PFA testing will only contribute to the identification of a subset of patients with non-cardiac symptoms, with both the size of the subset and potential value of the test dependent on the threshold used to define 'prolonged' closure times.
- Limitations of this pilot study include the enrollment of patients via convenience sampling, the fact that patient outcomes were not monitored beyond hospital discharge, and that a risk/benefit analysis was not included in the study design.

For peer review only

1  
2  
3 Accurate, efficient and cost-effective diagnosis of patients presenting to emergency  
4 departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS) – and, in  
5 particular, the exclusion and early discharge of patients with non-cardiac chest pain – is a  
6 growing priority [1, 2]. In an effort to meet this challenge, interest has focused on the  
7 identification of new approaches to augment standard ED procedures and facilitate the timely  
8 triage of patients with suspected ACS. For example, there is recent evidence that coronary CT  
9 angiography (CCTA) combined with routine clinical assessment may provide added prognostic  
10 value in the management of chest pain patients in the ED [3-8]. Use of CCTA in low-to-  
11 intermediate risk patients is reportedly safe and reduces ED costs and hospital length of stay [3-  
12 5, 7, 8]. However, these benefits are accompanied by exposure to radiation and associated  
13 with increases in diagnostic testing and subsequent invasive procedures [5, 8].

14  
15  
16 Assessment of platelet activation, an early feature in the pathogenesis of ACS [9-14],  
17 has also been investigated as a possible benign strategy to expedite the diagnosis of ACS [15,  
18 16]. Application of flow cytometry, the 'gold standard' for the quantitation of molecular indices of  
19 platelet activation, is, however, impractical for routine use under emergent conditions [11, 12,  
20 17, 18]. More importantly, classic molecular indices of platelet activation have not provided  
21 added benefit in the risk stratification of undifferentiated chest pain patients [15, 16].

22  
23  
24 We hypothesized that rapid assessment of platelet reactivity using a technically  
25 straightforward point-of-care device – specifically, the Platelet Function Analyzer (PFA)-100<sup>®</sup>  
26 (Siemens) – may represent a more feasible strategy to assist in the timely rule- out of ACS in  
27 the ED. Rather than quantifying molecular markers of platelet activation-aggregation, the output  
28 of the PFA-100<sup>®</sup> is 'closure time': that is, the time required for whole blood, aspirated under high  
29 shear, to occlude a small, 150 µm aperture in a membrane coated with standard platelet  
30 agonists (collagen-adenosine diphosphate [ADP] or collagen-epinephrine). Although the PFA-  
31 100<sup>®</sup> is typically utilized to investigate the responsiveness of patients to aspirin and other anti-  
32 platelet therapies and aid in the detection of platelet dysfunction [11, 12, 18-22], there is

1  
2  
3 evidence to suggest that shortened closure times may be a marker of the acuity of coronary  
4 disease [10]. Accordingly, our primary aims in this pilot study were to determine whether point-  
5 of-care testing of platelet function: (i) (may assist in the rule-out of ACS; (ii) may yield additional  
6 predictive value in identifying patients with non-cardiac symptoms *versus* ACS-positive patients;  
7 and (iii) is logistically feasible in an emergent setting. In addition, as a secondary analysis, we  
8 investigated whether closure time may be of value in discriminating between ST-elevation  
9 myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)/unstable  
10 angina (UA).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 METHODS

25  
26 We conducted a prospective cohort feasibility study of patients presenting with potential  
27 ACS at two urban tertiary care sites: the Emergency Department at the University of  
28 Massachusetts (UMASS)-Memorial Medical Center, University Campus, Worcester, MA USA,  
29 and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL, Cordoba,  
30 Argentina. The enrollment period was from January 2007 to December 2010. At each site,  
31 patients were entered on a convenience basis: i.e., enrollments were not consecutive but,  
32 rather, coincided with the work schedules of the study investigators. The protocol was reviewed  
33 and approved by the respective Institutional Review Boards at both institutions.  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Patient Population**

44  
45 Patients  $\geq 18$  years of age with a potential diagnosis of ACS (at the discretion of the  
46 treating physician and reflected by orders for an electrocardiogram (ECG) and cardiac  
47 biomarkers) were considered for enrollment in the study. Prospective exclusion criteria were  
48 pregnancy, renal insufficiency (defined as serum creatine levels  $\geq 1.5$  mg/dl), anemia  
49 (hematocrit  $< 30\%$ ), platelet count  $< 100,000/\mu\text{L}$ , major bleeding, any gastrointestinal bleeding,  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 trauma, or inability to provide informed consent for any reason. **The use of anti-platelet agents**  
4 **was not an exclusion criterion.**  
5  
6

### 7 ***Study Enrollment and Protocol***

8  
9  
10 As soon as possible after evaluation by ED staff, potential subjects were approached for  
11 enrollment into the study. If the patient was too ill or otherwise unable to provide written  
12 consent, then proxy consent was attempted. If consent was obtained by proxy and the patient  
13 later became cognizant, they were given the option to continue or withdraw their participation in  
14 the study. If consent was withdrawn, all collected data were discarded.  
15  
16  
17  
18  
19

20 **Blood used in the PFA-100<sup>®</sup> was drawn within <1 hour after presentation,** at the same  
21 time as cardiac biomarker testing, and closure time was measured within 3 hours of collection.  
22 All samples were obtained via peripheral venipuncture and drawn into tubes containing 3.2%  
23 sodium citrate. Immediately before analysis, each sample was gently inverted; a 900 µL aliquot  
24 of whole blood was then applied to a collagen-ADP test cartridge and closure time was  
25 quantified. Maximum test duration for the PFA-100<sup>®</sup> is 5 minutes; if the aperture is not occluded  
26 within this period, a closure time of '>300 seconds' is displayed.  
27  
28  
29  
30  
31  
32  
33  
34

35  
36 Upon enrollment, patients were questioned regarding a history of bleeding or platelet  
37 function disorders and ingestion of known anti-platelet agents within the past 7 days (aspirin,  
38 clopidogrel, non-steroidal anti-inflammatory agents). In addition, the medical record was  
39 reviewed and standard cardiac risk factors (diabetes, hypertension, hypercholesterolemia,  
40 smoking, family history of heart disease) were recorded and used in the calculation of TIMI risk  
41 score [23].  
42  
43  
44  
45  
46  
47  
48

### 49 ***Patient Diagnosis***

50  
51 Final diagnosis (**non-cardiac symptoms versus ACS-positive**) was established via  
52 standardized chart review. All reviews were conducted by physicians in a blinded manner,  
53 without knowledge of the closure time data. **For subjects enrolled at the Instituto Modelo de**  
54 **Cardiologia Privado, patients were seen by a cardiologist at the time of hospital presentation,**  
55  
56  
57  
58  
59  
60

1  
2  
3 and all reviews were performed by a team of cardiologists (WQC, GFT, FRZ, ECC, JPS). At  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

and all reviews were performed by a team of cardiologists (WQC, GFT, FRZ, ECC, JPS). At  
UMASS, each patient was first seen by an Emergency Medicine physician at the time of hospital  
presentation, and each chart was reviewed by an ED physician (CED). For patients with a  
definitive diagnosis of non-cardiac symptoms (that is, patients with no ischemic ECG changes,  
no positive markers or provocative cardiovascular test results, and no history of a diagnosis of  
ACS of any type in the chart), no additional review was performed. However, for patients who:  
(i) had positive cardiac biomarkers during admission; (ii) underwent cardiac catheterization; (iii)  
had a positive provocative cardiovascular test (e.g., exercise stress test); or (iv) had ischemic  
ECG changes, the chart was reviewed by both an ED physician and a cardiologist. In any case  
in which the diagnosis was uncertain, the decision was adjudicated by a cardiologist (CSS).

Patients considered to be ACS-positive were categorized into one of two groups, STEMI  
or NSTEMI/UA, in accordance with standard guidelines [24-26]. Patients who did not meet  
these criteria were classified as having a diagnosis of non-cardiac chest pain/symptoms.

### **Statistical Analysis**

Our target sample size in this exploratory study was empiric. We reasoned that, as an  
approximate order of magnitude, ~100 patients would be required in the ACS-positive group in  
order to have a likelihood of discerning a potential difference in closure times between patients  
with non-cardiac symptoms and the ACS-positive cohort. Assuming that 75% of patients  
enrolled in the study would have a diagnosis of non-cardiac chest pain (and thus 25% would be  
ACS-positive), a total of approximately 400 patients would be required. To account for  
exclusions, target enrollment was set at ~500 subjects.

### **Univariate comparisons**

Our primary analyses focused on the comparison of patients in the two main outcome  
groups: non-cardiac symptoms *versus* ACS-positive. All categorical data were compared using  
the Fisher's Exact Test and are reported as percentages. For continuous data, the D'Agostino  
and Pearson Test was applied to determine normality and the appropriate parametric (t-test) or

1  
2  
3 non-parametric alternative (Mann-Whitney) tests were utilized. Secondary analysis (comparison  
4 of closure times among non-cardiac chest pain, STEMI and NSTEMI/UA groups) was  
5  
6 of closure times among non-cardiac chest pain, STEMI and NSTEMI/UA groups) was  
7  
8 conducted using the Kruskal-Wallis test. Results are reported as mean  $\pm$  standard deviation or  
9  
10 medians with associated 10<sup>th</sup> and 90<sup>th</sup> percentile ranges.

### 11 Sensitivity, specificity and multivariate analysis

12  
13  
14 We made the prospective and arbitrary decision to categorize closure time into “normal”  
15  
16 and “prolonged” values based on the 90<sup>th</sup> percentile of the distribution for all patients enrolled in  
17  
18 the study. Utilizing the normal and prolonged values of closure time, the sensitivity, specificity,  
19  
20 negative and positive predictive values and likelihood ratio for identifying patients with **non-**  
21  
22 **cardiac symptoms** were determined. Two reasons contributed to our choice of non-cardiac  
23  
24 chest pain (rather than ACS positive) as the main outcome of interest: (i) this approach is  
25  
26 consistent with current guidelines for the improvement of diagnostic accuracy [1, 8]; and (ii) we  
27  
28 reasoned that prolonged closure times may be associated with the absence of ACS, whereas  
29  
30 shorter closure times may be manifest in either group of patients. Sensitivity, specificity,  
31  
32 predictive values and the likelihood ratio are reported with associated 95% confidence intervals.  
33  
34

35  
36 To determine if PFA closure time provides additional predictive value to standard clinical  
37  
38 diagnostic information, a logistic regression was developed to assess its independent  
39  
40 association with the main outcome of non-cardiac symptoms. Independent predictor variables  
41  
42 considered to be mandatory in the model were closure time (utilizing continuous rather than the  
43  
44 categorized values; the main predictor of interest) and the TIMI risk score (representing  
45  
46 standard clinical information to predict ACS outcomes). To account for potential differences  
47  
48 between UMASS and Cordoba, study site was also added to the regression model. Other non-  
49  
50 mandatory variables considered for inclusion were sex, a medical history of diabetes,  
51  
52 hypertension, hypercholesterolemia, smoking, and clopidogrel use. As age and aspirin use are  
53  
54 individually incorporated in the TIMI risk score, these variables were not considered for separate  
55  
56 inclusion in the model. Non-mandatory variables were left in the model only if they yielded an  
57  
58  
59  
60

1  
2  
3 increase in predictive value as determined by ROC (receiver operating characteristic) analysis  
4  
5 or were of additional importance based on the 2 log likelihood ratio test.  
6  
7

8 The reported estimate and adjusted odds ratio for closure time were calculated for an  
9  
10 increase in platelet closure time of 10 seconds (rather than 1 second), a choice based on the  
11  
12 premise that a 1-second increase would be of limited clinical usefulness. The final model was  
13  
14 evaluated by c-statistic (area under the ROC curve) and the Hosmer and Lemeshow fit test. As  
15  
16 a sensitivity test, the results were calculated using the general estimating equation (PROC  
17  
18 GENMOD) with study site evaluated as a subject factor (cluster) rather than a term in the model.  
19  
20 **The Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI) statistic**  
21  
22 **were not included in the analyses, given the skepticism and criticisms that have been raised**  
23  
24 **concerning their value in predicting the potential, incremental prognostic impact of novel**  
25  
26 **biomarkers [27, 28].**  
27  
28

29 Analyses were performed using GraphPad Prism Version 5.04 (San Diego CA) and  
30  
31 SAS Version 9.3, (Carey NC).  
32  
33  
34  
35

## 36 RESULTS

### 37 ***Enrollment and exclusions*** (Figure 1)

38  
39 A combined total of 509 patients were enrolled at the two study sites. Sixty-one subjects  
40  
41 were excluded because closure time data were not available: reasons included technical errors  
42  
43 (n=14), closure times >300 seconds (possibly due to mild thrombocytopenia, anemia, or  
44  
45 inadequate mixing of the blood sample prior to testing; n=36), and failure to measure closure  
46  
47 time despite obtaining consent (n=11). An additional 5 subjects were removed from analysis  
48  
49 because exclusion criteria were identified after consent was obtained (n=4), or consent was  
50  
51 revoked after the blood sample was collected (n=1). For the remaining 443 patients in whom  
52  
53 closure time was quantified, 8 were diagnosed with thrombotic events that were non-cardiac in  
54  
55 origin and thus were excluded from further analysis. Accordingly, results are reported for 435  
56  
57  
58  
59  
60

1  
2  
3 subjects (324 enrolled at UMASS and 111 enrolled in Cordoba): 105 were diagnosed with ACS  
4  
5 and 330 had non-cardiac symptoms.  
6

7 **Demographics** (Table 1)  
8

9  
10 As expected [29], the ACS-positive group had higher TIMI scores, was older, and had a  
11 higher proportion of male subjects *versus* patients with non-cardiac symptoms. In addition, the  
12 incidence of hypercholesterolemia and use of clopidogrel were significantly higher in the ACS  
13 group. There were, however, no differences in the use of aspirin, incidence of hypertension or  
14 diabetes, proportion of smokers or reported family history of heart disease between the two  
15 groups.  
16  
17  
18  
19  
20  
21

22 **Closure time** (Figure 2 and Table 2)  
23

24  
25 There was a modest but significant difference in median closure times in patients with  
26 non-cardiac symptoms *versus* the ACS-positive group: 91 *versus* 87 seconds, respectively  
27 (p=0.0061; Figure 2A). **When the ACS-positive group was divided into STEMI and combined**  
28 **NSTEMI/UA cohorts, the modest differences in closure time in the secondary 3-group analysis**  
29 **remained significant (p=0.0001; Figure 2C).**  
30  
31  
32  
33  
34  
35

36 Of potentially greater importance, patients with non-cardiac symptoms *versus* ACS-  
37 positive patients were distinguished by differences in the proportion of prolonged closure times.  
38 We found that 41/330 (12.4%) of patients with non-cardiac symptoms had closure times  $\geq$  138  
39 seconds (i.e., the 90<sup>th</sup> percentile of the distribution for all patients enrolled in the study) while, in  
40 contrast, 2/105 (1.9%) of patients in the ACS-positive group had closure times  $\geq$  this value  
41 (p=0.0006; Figure 2B and Table 2A). The specificity and sensitivity of 'prolonged' closure times  
42 ( $\geq$  138 seconds) for a diagnosis of non-cardiac symptoms were 98.1% and 12.4%, respectively,  
43 with positive a positive predictive value of 95.4%, negative predictive value of 26.3%, and  
44 **likelihood ratio of 6.52** (Table 2B).  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Site Differences: UMASS versus Cordoba** (Table 3)

Patients at both sites displayed the expected differences in TIMI score, age and sex between non-cardiac chest pain and ACS-positive groups (data not shown). However, subjects enrolled in Cordoba were significantly younger, with a higher proportion of males and smokers but lower proportion of diabetics, when compared with UMASS (Table 3). In addition, and as expected [30, 31], aspirin use was significantly lower among the cohort in Cordoba *versus* the UMASS population (40% *versus* 80%,  $p < 0.0001$ , Table 3). Despite these demographic differences, a higher incidence of prolonged closure times in patients with non-cardiac symptoms was observed at both sites: i.e., the proportion of subjects with closure times  $\geq 138$  seconds was 13.0% *versus* 10.0% in patients with non-cardiac chest pain and 1.9% *versus* 2.0% in ACS-positive patients at UMASS *versus* Cordoba, respectively.

**Closure time as an independent predictor of diagnosis** (Table 4)

Logistic regression analysis was first performed with both mandatory variables (closure time, TIMI risk score) and non-mandatory variables (study site, sex, diabetes, hypertension, hypercholesterolemia, smoking, clopidogrel use) included in the regression model (data not shown). ROC analysis revealed that, among the non-mandatory variables, only study site (UMASS *versus* Cordoba) contributed to an increase to the predictive value of the model for a diagnosis of non-cardiac symptoms. **Comparison of ROC curves obtained by including closure time, TIMI score and site in the model *versus* TIMI score and site alone showed a significant, incremental increase in area under the curve with the addition of closure time (0.818 *versus* 0.795;  $p = 0.009$ ; Figure 3).** Accordingly, the final multivariate logistic regression model incorporated these three variables (Table 4).

For every 10-second increase in closure time, the adjusted odds of a diagnosis of non-cardiac symptoms was 1.17 (95% confidence interval: 1.06 to 1.29). That is, when controlling for TIMI risk score and study site: for every 10 second increase, the prolonged closure time was associated with a 17% increase in the patient having non-cardiac chest pain. These results

1  
2  
3 demonstrate that, *irrespective of TIMI score and site*, closure time was associated with the  
4 diagnosis of non-cardiac symptoms, with *closure time providing additional, incremental*  
5 *predictive value beyond that obtained by TIMI score*. The model demonstrated good predictive  
6 characteristics ( $c=0.82$ ) and model fit ( $\chi^2=5.24$ ,  $df=8$ ;  $p=0.73$ ). Finally, the sensitivity analysis  
7 that utilized a general estimating equation accounting for potential correlations among sites did  
8 not result in any important changes in the direction of the effects (adjusted odds for every 10  
9 second increase in closure time: 1.15 with 95% confidence interval 1.10 to 1.23) or  
10 conclusions.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

## 23 DISCUSSION

24  
25 In this study, we demonstrate that point-of-care testing of platelet reactivity using the  
26 PFA-100<sup>®</sup> is feasible in the environment of the ED. Results of our primary analysis revealed  
27 differences in closure times between patients with non-cardiac symptoms *versus* ACS-positive  
28 cohorts, with the most notable, discriminating feature being the higher incidence of prolonged  
29 closure times in the group with non-cardiac chest pain. Finally, the outcome of our multivariate  
30 analysis is consistent with the concept that assessment of closure time provides incremental,  
31 independent prognostic value beyond that obtained using the standard clinical predictor of TIMI  
32 score.  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 ***Assessment of platelet reactivity as a diagnostic tool for ACS in emergent settings***

43  
44 It is well-established that heightened platelet activity occurs in the setting of ACS [9-11,  
45 13, 14, 32]. Indeed, measurement of platelet reactivity has been utilized in an effort to discern  
46 the stability of coronary disease [10], predict the future incidence and outcomes of major  
47 adverse cardiovascular events [11, 33-37], and, although results have been disappointing, guide  
48 the dosing of anti-platelet agents with the goal of improving outcomes [32, 38, 39]. Our current  
49 study differs from these previous reports, in that it focused on the assessment of platelet  
50 reactivity as an adjunct strategy to risk stratify-patients with potential ACS in emergent  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 conditions. Accordingly, the novelty of our study lies in our expanded analysis of closure time,  
4 and the identification of a more practical and feasible application of these data in the prognosis  
5 of ACS.  
6  
7  
8

9  
10 Our observation of a modest but significant reduction in median/mean closure times in  
11 patients with ACS is consistent with the outcomes of two previous, small ED studies [40, 41].  
12 However, this ~4 second difference is of limited practical significance given the broad and  
13 overlapping distributions of closure times for patients with non-cardiac symptoms and the ACS-  
14 positive cohort (Figure 2). Rather, we propose **that the clinical utility of this test lies in the**  
15 **identification of patients with a prolonged closure time**, a threshold that we objectively  
16 defined as the 90<sup>th</sup> percentile of the distribution of the study population. In this regard, we found  
17 that prolonged closure time ( $\geq 138$  seconds) had a high specificity, positive predictive value and  
18 **likelihood ratio** for a diagnosis of non-cardiac chest pain.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Strengths and weaknesses**

30  
31 The results of our pilot study are consistent with the hypothesis that point-of-care testing  
32 of platelet reactivity may assist in the timely rule-out of ACS in the ED. Strengths of this  
33 approach include the fact that assessment of closure time is technically straightforward and  
34 cost-effective, with minimal patient risk (i.e., does not involve exposure to radiation or additional  
35 invasive testing). In addition, our data suggest that the concept is generalizable. **We observed**  
36 **significant differences in demographics (age and gender), the prevalence of specific risk factors**  
37 **(diabetes, smoking) and the use of anti-platelet therapy (aspirin: Table 3) between UMASS and**  
38 **Cordoba – findings that are in agreement with published reports focused on Argentine cohorts**  
39 **[30, 31, 42], and may underlie the robust contribution of study site as a predictor of outcome in**  
40 **our logistic regression model.** Nonetheless, our results, obtained from two distinct health care  
41 systems and populations, consistently revealed a higher proportion of prolonged closure times  
42 in patients with non-cardiac symptoms.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There is, however, an important caveat to this strategy. PFA testing will only contribute to the identification of a subset of patients with non-cardiac symptoms, with both the size of the subset and potential value of the test dependent on the threshold used to define 'prolonged' closure times (Figure 2 and Table 5). For example, the prospective and **arbitrary criterion** used in our analysis (the 90<sup>th</sup> percentile of closure times for all patients enrolled in the study) discerned an arguably modest, 12.4% of patients with a diagnosis of non-cardiac symptoms. However, expediting the discharge of even a small proportion of patients with a non-cardiac diagnosis would limit the costs, potential risks and patient stress associated with unneeded advanced diagnostic testing and possibly invasive procedures [1, 2]. Reducing the threshold (i.e., to the 80<sup>th</sup> percentile of the distribution) would increase the size of the subset identified as ACS-negative, with an accompanying (and increasingly unacceptable) loss in specificity because of the growing proportion of false-positives (ACS-positive patients with prolonged closure times: Figure 2 and Table 5). In contrast, increasing the threshold (i.e., to the 95<sup>th</sup> percentile) would identify a diminishing proportion of patients with non-cardiac symptoms with increasing specificity (Figure 2 and Table 5). The appropriate definition of 'prolonged' closure time will therefore require refinement based on risk/benefit analysis.

Finally, we emphasize that point-of-case assessment of platelet reactivity and identification of patients with 'prolonged' closure times clearly cannot function as a stand-alone test for the rule-out of ACS. Rather, measurement of PFA closure times may serve as an adjunct to current, standard ED practices. In support of this concept, our multivariate logistic regression model revealed that, irrespective of TIMI score and study site (and, thus, irrespective of differences in demographics and aspirin use between sites), closure time was an independent predictor of the diagnosis of non-cardiac symptoms.

### ***Summary, limitations and future directions***

We report that measurement of closure time using the PFA-100<sup>®</sup> provides additional and independent, incremental predictive value in the rule-out of ACS. Limitations of this pilot

1  
2  
3 feasibility study include the enrollment of patients via convenience sampling, and differences in  
4 the logistics of the chart review process between the two sites. In addition, neither monitoring of  
5 patient outcomes beyond hospital discharge (raising the possibility of potential misclassification  
6 of some patients) nor risk/benefit analysis of PFA testing was incorporated into the study  
7 design. We emphasize that point-of-care assessment of platelet reactivity cannot serve as a  
8 stand-alone test to either discern patients with non-cardiac symptoms *versus* ACS-positive  
9 patients or distinguish between STEMI versus NSTEMI/UA in the emergent setting – limitations  
10 that in all likelihood reflect the complex and multi-factorial pathophysiology of acute myocardial  
11 ischemia and infarction. Rather, our results suggest that assessment of closure times may  
12 provide benefit by augmenting standard ED diagnostic practices, a concept that warrants further  
13 large-scale multi-center investigation.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Funding Statement:**

Siemens Inc. provided the Emergency Department at the University of Massachusetts Medical School and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL with PFA-100<sup>®</sup> devices on a loan basis, as well as partial support for the purchase of test cartridges used in this study.

CED was supported in part by a Research Training Grant from the Society for Academic Emergency Medicine (SAEM), Des Plaines, IL.

The research received no additional, specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interests:** none

**Contributor Statement:**

Conception and design of the study: KP, CED, ADM

Analysis and interpretation of the data: all co-authors

Drafting of the manuscript or revising it critically for important intellectual content: KP, CED, RDW, PW, JASM, CSS, ADM

Final approval of the manuscript: all co-authors

All authors have had full access to all data and take responsibility for the integrity of the data and the accuracy of the analysis. KP is the guarantor.

## REFERENCES

1. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. *Circulation*. 2010;**122**:1756-76.
2. Darling CE, Michelson AD, Volturo GA, et al. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. *J Thromb Thrombolysis*. 2009;**28**:31-7.
3. Hollander JE, Chang AM, Shofer FS, et al. Coronary computed tomographic angiography for rapid discharge of low-risk patients with potential acute coronary syndromes. *Ann Emerg Med*. 2009;**53**:295-304.
4. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. *N Engl J Med*. 2012;**366**:1393-403.
5. Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. *N Engl J Med*. 2012;**367**:299-308.
6. Hoffmann U, Truong QA, Fleg JL, et al. Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. *Am Heart J*. 2012;**163**:330-8, 8 e1.
7. Singer AJ, Domingo A, Thode HC, Jr., et al. Utilization of coronary computed tomography angiography for exclusion of coronary artery disease in ED patients with low- to intermediate-risk chest pain: a 1-year experience. *Am J Emerg Med*. 2012;**30**:1706-11.

- 1  
2  
3 8. Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed  
4 tomography angiography in the emergency department: a systematic review and meta-  
5 analysis of randomized, controlled trials. *J Am Coll Cardiol.* 2013;**61**:880-92.  
6  
7
- 8  
9 9. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute  
10 coronary syndrome: results from the TIMI-12 trial. *Thrombolysis in Myocardial Infarction.*  
11  
12 *J Am Coll Cardiol.* 1999;**33**:634-9.  
13  
14
- 15 10. Linden MD, Furman MI, Frelinger AL, 3rd, et al. Indices of platelet activation and the  
16 stability of coronary artery disease. *J Thromb Haemost.* 2007;**5**:761-5.  
17  
18
- 19 11. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with  
20 coronary artery disease. *J Am Coll Cardiol.* 2007;**50**:1822-34.  
21  
22
- 23 12. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. *J*  
24 *Cardiovasc Pharmacol Ther.* 2009;**14**:157-69.  
25  
26
- 27 13. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. *Nat*  
28 *Rev Drug Discov.* 2010;**9**:154-69.  
29  
30
- 31 14. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. *J Am Coll Cardiol.*  
32  
33 2013;**61**:1-11.  
34  
35
- 36 15. Hollander JE, Muttreja MR, Dalesandro MR, et al. Risk stratification of emergency  
37 department patients with acute coronary syndromes using P-selectin. *J Am Coll Cardiol.*  
38  
39 1999;**34**:95-105.  
40  
41
- 42 16. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating  
43 monocyte-platelet aggregates in patients with stable coronary artery disease. *J Am Coll*  
44 *Cardiol.* 1998;**31**:352-8.  
45  
46
- 47 17. Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of platelet function by flow  
48 cytometry. *Methods.* 2000;**21**:259-70.  
49  
50
- 51 18. Michelson AD. Methods for the measurement of platelet function. *Am J Cardiol.*  
52  
53 2009;**103**:20A-6A.  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 **19.** Crescente M, Mezzasoma AM, Del Pinto M, et al. Incomplete inhibition of platelet  
4 function as assessed by the platelet function analyzer (PFA-100) identifies a subset of  
5 cardiovascular patients with high residual platelet response while on aspirin. Platelets.  
6 2011;**22**:179-87.  
7
- 8  
9  
10  
11 **20.** Linnemann B, Schwonberg J, Rechner AR, et al. Assessment of clopidogrel non-  
12 response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.  
13 Ann Hematol. 2010;**89**:597-605.  
14
- 15  
16  
17 **21.** Poulsen TS, Jorgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients  
18 with an evolving acute myocardial infarction. Thromb Res. 2007;**119**:555-62.  
19
- 20  
21  
22 **22.** Poulsen TS, Mickley H, Korsholm L, et al. Using the Platelet Function Analyzer-100 for  
23 monitoring aspirin therapy. Thromb Res. 2007;**120**:161-72.  
24
- 25  
26  
27 **23.** Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST  
28 elevation MI: A method for prognostication and therapeutic decision making. JAMA.  
29 2000;**284**:835-42.  
30
- 31  
32  
33 **24.** O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the  
34 management of ST-elevation myocardial infarction: executive summary: a report of the  
35 American College of Cardiology Foundation/American Heart Association Task Force on  
36 Practice Guidelines. Circulation. 2013;**127**:529-55.  
37
- 38  
39  
40  
41 **25.** Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction.  
42 Circulation. 2012;**126**:2020-35.  
43
- 44  
45  
46  
47 **26.** Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update  
48 incorporated into the ACCF/AHA 2007 guidelines for the management of patients with  
49 unstable angina/non-ST-elevation myocardial infarction: a report of the American  
50 College of Cardiology Foundation/American Heart Association Task Force on Practice  
51 Guidelines. Circulation. 2013;**127**:e663-828.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 **27.** Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on  
4 integrated discrimination improvement and net reclassification index. *Stat Med.* 2013:  
5 Epub 5 April 2013.  
6  
7
- 8  
9 **28.** Kerr KF, Wang Z, Janes H, et al. Net reclassification indices for evaluating risk prediction  
10 instruments: a critical review. *Epidemiology.* 2013: Epub 14 November, 2013.  
11  
12
- 13 **29.** Kelly AM. What is the incidence of major adverse cardiac events in emergency  
14 department chest pain patients with a normal ECG, Thrombolysis in Myocardial  
15 Infarction score of zero and initial troponin  $\leq$ 99th centile: an observational study?  
16 *Emerg Med J.* 2013;**30**:15-8.  
17  
18
- 19 **30.** Bernardi V, Szarfer J, Summay G, et al. Long-term versus short-term clopidogrel therapy  
20 in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel  
21 Stent [RACS] trial). *Am J Cardiol.* 2007;**99**:349-52.  
22  
23
- 24 **31.** Bernztein RG, Drake I. Use of aspirin in the public primary care level: experience of the  
25 Remediar Program, Argentina. *Rev Argent Cardiol.* 2010;**78**:330-8.  
26  
27
- 28 **32.** Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for  
29 coronary stenting. *N Engl J Med.* 2012;**367**:2100-9.  
30  
31
- 32 **33.** Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine  
33 diphosphate in patients with stable cardiovascular disease predicts major adverse  
34 events despite antiplatelet therapy. *Platelets.* 2008;**19**:104-10.  
35  
36
- 37 **34.** Atiemo AD, Ng'Alla LS, Vaidya D, et al. Abnormal PFA-100 closure time is associated  
38 with increased platelet aggregation in patients presenting with chest pain. *J Thromb*  
39 *Thrombolysis.* 2008;**25**:173-8.  
40  
41
- 42 **35.** Bevilacqua S, Alkodami AA, Volpi E, et al. Risk stratification after coronary artery bypass  
43 surgery by a point-of-care test of platelet function. *Ann Thorac Surg.* 2009;**87**:496-502.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 **36.** Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the  
4 definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll*  
5 *Cardiol.* 2010;**56**:919-33.  
6  
7
- 8  
9 **37.** Breet NJ, van Werkum JW, Bouman HJ, et al. The relationship between platelet  
10 reactivity and infarct-related artery patency in patients presenting with a ST-elevation  
11 myocardial infarction. *Thromb Haemost.* 2011;**106**:331-6.  
12  
13
- 14 **38.** Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on  
15 platelet function testing after percutaneous coronary intervention: the GRAVITAS  
16 randomized trial. *JAMA.* 2011;**305**:1097-105.  
17  
18
- 19 **39.** Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual  
20 platelet reactivity after clopidogrel pre-treatment is associated with an increased  
21 ischemic risk during elective percutaneous coronary intervention. *J Am Coll Cardiol.*  
22 **2013**;**61**.  
23  
24
- 25 **40.** Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in  
26 patients with acute myocardial infarction. *Circulation.* 2004;**110**:1392-7.  
27  
28
- 29 **41.** Harrison P, Mackie I, Mathur A, et al. Platelet hyper-function in acute coronary  
30 syndromes. *Blood Coagul Fibrinolysis.* 2005;**16**:557-62.  
31  
32
- 33 **42.** Moran A, Degennaro V, Ferrante D, et al. Coronary heart disease and stroke attributable  
34 to major risk factors is similar in Argentina and the United States: the Coronary Heart  
35 Disease Policy Model. *Int J Cardiol.* 2011;**150**:332-7.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURE LEGENDS

**Figure 1: Inclusion flow-chart.**

**Figure 2: PFA closure time (seconds).** (A) Median values with 10<sup>th</sup>, 25<sup>th</sup>, 75<sup>th</sup> and 90<sup>th</sup> percentiles: ACS-positive patients and patients with non-cardiac symptoms. (B) Individual data points for all subjects: ACS-positive patients and patients with non-cardiac symptoms. Lines denote the 80<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> percentiles of closure times for all patients enrolled in the study. (C) Individual data points for all subjects: STEMI, NSTEMI/UA cohorts and patients with non-cardiac symptoms. Lines denote the 80<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> percentiles of closure times for all patients enrolled in the study.

**Figure 3: ROC analysis.** Comparison of ROC curves obtained by including closure time, TIMI score and study site in the regression model *versus* TIMI score and site alone showed a significant, incremental increase in area under the curve with the addition of closure time (0.818 *versus* 0.795; p=0.009).

**Table 1.**  
**Demographics: All Patients**

	<b>Non-Cardiac Symptoms</b> (total n=330)	<b>ACS-Positive</b> (total n=105)	<b>p-value</b>
Age (years): mean $\pm$ SD	57 $\pm$ 14 (n=328)	61 $\pm$ 13 (n=104)	0.034
Male	65% (n=330)	80% (n=105)	0.004
TIMI score: mean $\pm$ SD	1.9 $\pm$ 1.4 (n=320)	3.1 $\pm$ 1.4 (n=104)	<0.0001
Aspirin	71% (n=321)	64% (n=104)	0.222 (ns)
Clopidogrel	11% (n=325)	20% (n=104)	0.031
Smoker	29% (n=322)	28% (n=105)	0.901(ns)
Hypertension	57% (n=322)	62% (n=105)	0.425 (ns)
Hypercholesterolemia	57% (n=322)	69% (n=105)	0.030
Diabetes	24% (n=322)	27% (n=105)	0.601 (ns)
Family History	40% (n=319)	41% (n=105)	0.909 (ns)

Table 2A.

**Incidence of Prolonged Closure Time**  
 ( $\geq 138$  seconds, defined as the 90<sup>th</sup> percentile of the distribution of the study population)

	<b>Non-Cardiac Symptoms</b>	<b>ACS-Positive</b>	<b>Total</b>
<b>Prolonged closure time: Yes</b>	41	2	43
<b>Prolonged closure time: No</b>	289	103	392
<b>Total</b>	330	105	435

Table 2B.

**Sensitivity, Specificity, Positive and Negative Predictive Values and Likelihood Ratio of Prolonged Closure Time for a Diagnosis of Non-Cardiac Symptoms**

Sensitivity	12.4%	95% confidence interval: 9.1% to 16.5%
Specificity	98.1%	95% confidence interval: 93.3% to 99.8%
Positive predictive value	95.4%	95% confidence interval: 84.2% to 99.4%
Negative predictive value	26.3%	95% confidence interval: 22.0% to 30.9%
<b>Likelihood ratio:</b>	<b>6.52</b>	<b>95% confidence interval: 1.61 to 26.51</b>

**Table 3.**  
**Demographics: UMASS vs Cordoba**

	<b>UMASS-All (total n=324)</b>	<b>Cordoba-All (total n=111)</b>	<b>p-value</b>
Age (years): mean $\pm$ SD	59 $\pm$ 14 (n=324)	56 $\pm$ 12 (n=108)	0.036
Male	65% (n=324)	78% (n=111)	0.009
TIMI score: mean $\pm$ SD	2.3 $\pm$ 1.5 (n=313)	2.0 $\pm$ 1.4 (n=111)	0.142 (ns)
Aspirin	80% (n=314)	40% (n=104)	<0.0001
Clopidogrel	15% (n=319)	9% (n=111)	0.146 (ns)
Smoker	26% (n=316)	37% (n=111)	0.038
Hypertension	61% (n=316)	51% (n=111)	0.093 (ns)
Hypercholesterolemia	62% (n=316)	53% (n=111)	0.115 (ns)
Diabetes	28% (n=313)	14% (n=111)	0.005
Family History	44% (n=313)	31% (n=51)	0.014

Table 4.

**Multivariable Logistic Regression Model**  
(outcome modeled: **Non-Cardiac Symptoms**)

<b>Predictor</b>	<b>Adjusted Odds Ratio</b>	<b>95% Confidence Interval</b>
Closure Time	1.17	1.06 to 1.29
TIMI Risk Score	0.48	0.40 to 0.59
Study Site (UMASS <i>versus</i> Cordoba)	7.21	4.05 to 12.86



Table 5.


Effect of Definition of 'Prolonged' Closure Time on  
Specificity and Positive Predictive Value for a **Diagnosis of Non-Cardiac Symptoms**

Threshold	Specificity	Positive Predictive Value	% of Patients with Non-Cardiac Symptoms Identified
<b>95<sup>th</sup> percentile (≥ 160 seconds)</b>	100% [96.6% to 100%]	100% [83.9% to 100%]	6.4% (21/330)
<b>90<sup>th</sup> percentile (≥ 138 seconds)</b>	98.1% [93.3% to 99.8%]	95.4% [84.2% to 99.4%]	12.4% (41/330)
<b>80<sup>th</sup> percentile (≥ 117 seconds)</b>	88.6% [80.9% to 94.0%]	86.2% [77.2% to 92.7%]	22.7% (75/330)

95% confidence intervals shown in square brackets


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1.



200x259mm (300 x 300 DPI)


Figure 2.



194x270mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 3.



194x206mm (300 x 300 DPI)

